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Zusammenfassung 
Noch immer ist die Schere zwischen der Produktion und großtechnischer 
Nutzung von Nanopartikeln einerseits und deren toxikologischen Potenti-
als andererseits recht groß. In vitro-Versuche sind ein oft genutztes Mittel 
zur Bestimmung der Toxizität von Substanzen, für Nanopartikel jedoch 
müssen in diesem Zusammenhang bestimmte Fallen erkannt und um-
gangen werden, um so generierte Ergebnisse richtig zu interpretieren. 
Eine Besonderheit von Nanopartikeln ist deren Interaktion mit Proteinen 
in Zellkulturmedien, aber auch mit physiologisch relevanten Proteinen. 
Einerseits können solche Interaktionen einen Einfluss auf den Agglome-
rationsgrad der Partikel, andererseits auf die Reaktion der Zelle auf einen 
solchen, mit Proteinen überzogenen Partikel haben. Somit kann sich das 
toxikologische Potential von Nanopartikeln in beide Richtungen verschie-
ben.  
Bei Untersuchungen mit dem Modellprotein BSA bzw. FCS konnten Un-
terschiede in der Adsorption an drei Nanopartikel gleichen Materials als 
auch sehr ähnlichen physikalisch-chemischen Eigenschaften aufgezeigt 
werden. Dabei zeigte sich, dass BSA wahrscheinlich in unterschiedlichen 
Konformationen an die Partikel bindet. Außerdem muss, um Proteinad-
sorption richtig einschätzen zu können, der Agglomerationsgrad der Par-
tikel mit einbezogen werden.  
Protein-Adsorption konnte nicht nur für Modellproteine, sondern auch 
für das physiologisch relevante Surfactant Protein A an acht verschiede-
ne Partikel, teilweise aus gleichem Material, nachgewiesen werden. Im 
Gegensatz zu BSA hat die Dispersion in Sp-A-haltigem Medium keinen 
positiven Einfluss auf das Deagglomerationsverhalten der Partikel.  
Inhalierte Partikel können möglicherweise die Blut-Luft-Schranke passie-
ren und so in den Blutkreislauf gelangen. Um den Partikelübertritt zu 
untersuchen, wurde ein in vitro Zellkultur-Modell an die Besonderheiten 
von Transportversuchen mit Nanopartikeln angepasst. Die Zellkultur-
Bedingungen wurden angepasst und anschließend die Transporteigen-
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schaften der Zellen mit diesen veränderten Gegebenheiten bestätigt. Mit 
Ausnahme der beiden getesteten CeO2-Partikel konnte im Rahmen der 
Versuchsdurchführung bei keinem Nanopartikel ein Transport festge-
stellt werden. 
 
Schlagwörter:  
Metalloxid-Nanopartikel, Nanotoxikologie, Proteinadsorption, Partikel-
transport
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Abstract 
There is still a big gap between nanoparticle production and industrial 
use on one hand and the knowledge of their toxicological potential on the 
other. In vitro assays are a common tool to investigate toxicity of sub-
stances, but for nanoparticles, some especially dispersion related pitfalls 
must be recognized and bypassed prior to correct interpretation of re-
sults. One special feature of nanoparticles is the possible interaction with 
proteins in cell culture media and with physiological proteins as well. On 
one hand, those interactions can have an influence on the agglomeration 
state, on the other hand cell reactions and hence the toxicological poten-
tial can be altered.  
Investigations with the model protein BSA or FCS, respectively, revealed 
differences for the adsorption onto nanoparticles, although the particles 
tested had very similar physico-chemical properties. BSA seemed to ad-
sorb to the particles in different conformations, and the state of agglom-
eration must be taken into account to draw conclusions about protein 
adsorption. 
Protein adsorption was also confirmed for physiologically relevant Surfac-
tant protein A to eight different nanoparticles of partially the same bulk 
material. Also here, differences in protein adsorption could be detected. 
In contrast to BSA, Sp-A does not have much impact on the agglomera-
tion state of the particles. 
Inhaled particles might cross the air-blood barrier and enter the blood 
stream. Hence, an in vitro air-blood barrier model was adapted to 
transport experiments with nanoparticles. The cell culture conditions 
were adapted and the transport characteristics of the cells confirmed. 
Except two different CeO2 particles, no metal oxide nanoparticle 
transport could be detected.  
 
 
 
 VI 
Keywords:  
metal oxide nanoparticle, nanotoxicology, protein adsorption, particle 
transport 
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1 Background and aim of this thesis   
1.1 Nanoparticles 
Nanotechnology is a key technology of the 21st century. Nanoparticles 
are used in many industrial sectors, as micro-electronics, materials, pa-
per, textile, energy, and cosmetics [1, 2]. The industrial relevance is ex-
pressed in an estimated annual turnover of nanoparticle-based products 
in the range of 1.1 - 2.5 trillion us dollars by the year 2015 [3]. The ad-
vantages of nanotechnology are the production of  light and endurable 
materials, cleaner energy, inexpensive clean water production, as well as 
several beneficial pharmaceutical and medical applications [1, 4]. Nano-
particles are defined as particles with at least one dimension smaller 
than 100 nm [5], the dimensions are compared in Figure 1.1. The very 
high surface to mass ratio gives them their unique properties, which are 
summarized in Table 1.1. This surface to mass ratio is not changed sig-
nificantly by agglomeration or aggregation. Thereby, aggregates and ag-
glomerates also count as nanoparticles even if their size is much bigger, 
but only if the size of the primary particles does not exceed 100 nm. 
Hence, an additional definition based on the particle surface is discussed 
and a lower limit of 60 m2/g suggested (corresponding to the specific sur-
face area of spherical particles of 100 nm in diameter and unit density) 
[5]. 
 
Table 1.1. Unique features of nanomaterials (adopted from [6]) 
Size: 
 20-50 nm enters CNS 
 70 nm, able to escape defense system in vivo 
High surface to mass ratio 
High strength, conductivity, solubility, durability and reactivity 
Catalytic promotion of reactions 
Ability to adsorb and carry other compounds 
Ability to escape defense system in vivo 
Ability to cross cellular and sub-cellular membranes 
Surface coating (e.g. lecitin, albumin) 
 Enhance uptake by type I/II pneumocytes 
 Transcytosis across capillary 
Charged particle (higher inhaled deposition) 
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Figure 1.1. a) Comparison of a microparticle of 60 µm diameter (about the 
size of a human hair) with particles of 600 nm and 60 nm, respectively. 
When all particles have the same mass, a reduction of the diameter of 1 
decade increases the number of particles one thousand fold. b) Surface area 
normalized to mass versus particle diameter, i.e. decreasing particle diame-
ter is leading to exponentially growing particle surface area (Illustration 
adopted and modified from [7])  
 
 
1.2 Project NanoCare 
The benefits of nanoparticles are opposed to unknown health risks, as 
the development of new nanoparticles exceeds their toxicological risk as-
sessment by far. In the late 1990´s, a perception of possible health risks 
came up and first guidelines were developed [8]. Kuhlbusch and co-
workers and Bower and co-workers published the first studies related to 
exposure of engineered nanoparticles [9-11], the first publications related 
to nanotoxicology date back to 1992, e.g. Oberdörster and co-workers 
[12]. As the gap between nanoparticle production and nanoparticle safety 
research was still very big, the German Federal Ministry of Education 
and Research (Bundesministerium für Bildung und Forschung, BMBF) 
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initiated a trilogy of projects: INOS, TRACER and NanoCare. The aim of 
TRACER was the evaluation of biocompatibility, especially cytotoxicity of 
Carbonanotubes (CNTs), along the value creation chain of CNTs. INOS 
contributed to the risk assessment of ceramic and metal nanoparticles, 
based on in vitro methods. The NanoCare project was a cooperation of 13 
partners from university, industry and research institutes that developed 
a research plan concerning the risk assessment of nanomaterials and 
started in March 2006. NanoCare aimed to sustain nanoparticle devel-
opment, combining the identification of possible exposure and hazard of 
new industrially relevant nanoparticles with the innovation in material 
science. As a possible human or ecological hazard significantly influences 
the public perception of nanoparticles negatively, nanotechnology might 
not be accepted and lead to nanotechnology crisis. Hence, NanoCare 
turned to three major routes: The first was knowledge generation, i.e. re-
search of nanoparticle exposure and toxicity in in vivo and in vitro test 
systems. The second was knowledge management, based on literature 
studies and the research work within the project. A combination of these 
data was fed into a partially public data base, so an exchange between 
the partners was possible at any time. Finally, knowledge transfer and 
communication was supposed to facilitate the exchange between scien-
tists and the public by explaining generated results in a generally under-
standable manner at workshops, dialogues and a website 
(www.nanopartikel.info). 
 
1.3 The human lung 
The human lungs can be divided into two functional regions. The con-
ducting airways, i.e. nose cavity, trachea, bronchi and several genera-
tions of bronchioles, direct the air to and from the respiratory zone. Con-
sisting of respiratory bronchioles and the alveoli, the respiratory zone is 
up to 140 m2 big [13] and  is the site of  gas exchange [14]. The columnar 
epithelium of the airways is gradually thinning, from 3-5 mm of the 
bronchial epithelium to 0.5-1 mm thickness of the bronchiolar epitheli-
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um [14, 15]. The tracheobronchiolar region is protected by a mucus layer, 
and landing foreign matter is transported towards the larynx via mucocil-
iary clearance [16]. However, the alveoli consist of type I and type II 
pneumocytes, whereas 93 % of the alveolar epithelial area is covered by 
type I cells [17]. The epithelial air-blood barrier here is only about 
400 nm thick [18]. Type II cells produce the Alveolar Lining Fluid (ALF), 
by which the alveolar region is covered. Pulmonary surfactant, a major 
component of ALF, is required for normal respiration, as it increases the 
surface tension forces at the air-ALF interface. This avoids the collapse of 
alveoli during exhalation and also reduces the force needed to ventilate 
them [19]. This lung surfactant contains of approximately 85-90 % phos-
pholipids (by weight), predominantly Phosphatidylcholine. Also, pulmo-
nary surfactant contains about 10 % proteins, the so called surfactant 
proteins A, B, C and D (Sp-A, Sp-B, etc., collective name Sp-X) [20]. The 
lipophilic Sp-B and Sp-C function as stabilizers for the surfactant film, 
whereas the hydrophilic Sp-A and Sp-D play a role in host defense. Sp-A 
is the most prominent of the four Surfactant proteins and is opsonizing 
bacteria by binding to carbohydrate groups with its lectin binding site 
[21]. Also, it is involved in the recycling of surfactant, i.e. the reuptake 
into type II pneumocytes [22]. This pulmonary surfactant represents the 
first barrier inhaled substances interact with, prior to contacting the al-
veolar epithelium. 
 
 
1.4 My contribution to the NanoCare Project and the subject of 
this work 
Generally, there are three possibilities for particles to enter the body: 
penetration through the skin, adsorption in the gastrointestinal tract or 
by inhalation. The most prominent exposure route for nanoparticles is 
the lung, as particle deposition in the airways is size-dependent (Figure 
1.2). The maximum of particle deposition in the alveoli with its immense 
size of up to 140 m2 lies with 10 to 100 nm exactly in the nanoparticle 
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range. Hence, the exposition as well as the inhalation toxicity of nanopar-
ticles plays a key role in nanoparticle risk assessment.  
 
 
 
 
Figure 1.2. a) The respiratory tract and b) the particle deposition as a func-
tion of size in a normal breathing male human at rest. The data of bronchi 
are the sum of deposition in bronchi and bronchioles (adopted from [23]). 
 
 
Inhalation is the most significant exposure route for airborne nanoparti-
cles [24, 25]. The distance between alveolar lumen and blood flow is with 
400 nm very small and combined with the large surface area of the alveo-
li those characteristics make this region less protected against inhaled 
substances compared to the conducting airways [26]. Hence, the particle 
interaction with lung barrier systems was investigated in in vitro models. 
This work as a part of the NanoCare project was the investigation of par-
ticle interaction with ALF as first barrier and permeation of nanoparticles 
through the lung into the blood stream. For this purpose, we used a well-
established in vitro model of the air-blood-barrier, i.e. Calu-3 cells grown 
on filter supports (Figure 1.3). Not every lung cell line is convenient for 
use in this model: the cells must display special epithelial barrier charac-
teristics, i.e. development of tight junctions, which parts the system in an 
apical and a basolateral compartment with a polarized epithelial mono-
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layer, denying passive diffusion processes, but allowing specific transport 
of substances. 
 
Figure 1.3. The Transwell system, containing of a filter insert and a permea-
ble filter support, on which cells with characteristic epithelial traits are cul-
tivated. With this model, nanoparticle transport through the cells (a), para-
cellular transport via opening of the tight junctions (b), uptake into the cell 
(c) as well as adsorption onto the cell surface (d) can be investigated.  
   
 
Prior to transport experiments, the particles must be characterized in the 
physiological medium used for testing, as those engineered mostly metal 
oxide nanoparticles used in the NanoCare project are not adapted to cell 
culture testing. 
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2 Not ready to use – overcoming pitfalls when dispers-
ing nanoparticles in physiological media 
 
The data presented in this chapter have been published in parts as a re-
search article in the journal Nanotoxicology: 
Christine Schulze, Alexandra Kroll, Claus-Michael Lehr, Ulrich F. 
Schaefer, Karsten Becker, Jürgen Schnekenburger, Christian Schulze 
Isfort, Robert Landsiedel, Wendel Wohlleben: Not ready to use - Overcom-
ing pitfalls when dispersing nanoparticles in physiological media. Nano-
toxicology 2008, 2:51-61. 
DOI: 10.1080/17435390802018378 
Web-Link: 
http://informahealthcare.com/doi/abs/10.1080/17435390802018378 
 
Contributions: 
I characterized the model polystyrene nanoparticle in the different media and contribut-
ed to the characterization of the metal oxide particles. Furthermore, I prepared the 
manuscript. 
Alexandra Kroll, Karsten Becker and Jürgen Schnekenburger from Westfälische Wil-
helms-Universität Münster,  Gastroenterologische Molekulare Zellbiologie, Medizinische 
Klinik und Poliklinik B and Institut für Medizinische Mikrobiologie, performed the En-
dotoxine study and sterility testing of the nanoparticles. 
Christian Schulze-Isfort (Evonic-Degussa GmbH, R & D Aerosil, Hanau, Germany) and 
Robert Landsiedel (BASF Aktiengesellschaft, Experimental Toxicology, Ludwigshafen, 
Germany) helped to interpret the results and partially characterized the TiO2 B particle. 
Wendel Wohlleben from BASF Aktiengesellschaft, Polymer Physics Research, Ludwigs-
hafen, Germany, performed the Analytical Ultracentrifugations and helped characterize 
the metal oxide particles. 
Ulrich F. Schaefer and Claus-Michael Lehr helped to discuss and interpret the results.  
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2.1 Abstract 
Industrial nanoparticles are not developed to be compatible with in vitro 
cell culture assays which are carried out in isotonic solutions at physio-
logical pH and often in the presence of proteins. The tendency of nano-
particles to deagglomerate or agglomerate is strongly sensitive to these 
parameters. The state of agglomeration and the protein corona bear an 
important influence on the level of toxic effects via the change of 
transport mechanisms and surface coating. Here we rigorously character-
ized the interaction of nanoparticles with physiological media for in-vitro 
nanotoxicology experiments. Beyond adsorption of proteins on metal ox-
ide and polymeric nanoparticles, we quantified nanoparticle deagglomer-
ation due to adsorbing proteins acting as protection colloids. We report 
on previously neglected, but indispensable testing of sterility and 
measures to ensure it. Our findings result in a checklist of pre-
requirements for dispersion of nanoparticles in physiological media and 
for reliable attribution of potential toxic effects.  
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2.2 Introduction 
Industrial NPs are not developed to be compatible with in vitro cell cul-
ture assays, as nano-suspensions use non-physiological pH values or 
cytotoxic stabilizing agents. Their tendency to deagglomerate or agglom-
erate is strongly sensitive to pH and ionic strength. For the use of NPs in 
in vitro assays, the dispersions must be isotonic, adapted to a pH of 7.4 
and applicable in the presence of divalent ions and protein mixtures. The 
interaction of the NPs with the wealth of other components in the physio-
logical media is one pitfall of nanotoxicology. Many individual aspects of 
NP dispersion and protein adsorption have been investigated recently 
[27-32], including the binding enthalpy of proteins on polymer particles 
[33] and the change of ζ-potential [30]. Due to the enormous colloidal 
polydispersity, size characterization constitutes in itself another major 
pitfall [34]. Ultrafine particles and agglomerates have to be quantified in 
an excess of proteins with 5 nm diameter (BSA monomer). Qualitatively, 
aqueous NP suspensions have been stabilized to prevent agglomeration 
by addition of BSA and FCS [31] and much enhanced dispersion has 
been observed for carbon nanotubes with a range of proteins [27, 29].  
Here, the interaction of nanoparticles with physiological media for in vitro 
nanotoxicological experiments were rigorously characterized and the ad-
sorption and drastic dispersing action of serum proteins with appropriate 
fractionating methods quantified. Also, the need of particle sterilization 
and methods to achieve this are presented.  
 
2.3 Materials & Methods 
Materials. The ingredients for phosphate buffer (PB; 50 mM; pH 7.4, 16 
mM NaH2PO4 , 33 mM Na2HPO4), isotonic phosphate buffer (50 mM; pH 
7.4, 10 mM NaH2PO4, 39 mM Na2HPO4, 2.4 mM NaCl) and Krebs-Ringer-
Buffer (KRB, 114.2 mM NaCl, 3 mM KCl, 1.5 mM K2HPO4 x 3 H2O, 10 
mM HEPES, 3.996 mM D-Glucose, 1.405 mM CaCl2, 2.562 mM MgCl2) as 
well as bovine serum albumin (BSA), Penicillin, Streptomycin, 
Amphotericin B and sodiumazide were purchased from Sigma-Aldrich 
Chemie GmbH, Munich, Germany. Dulbecco`s Modified Eagle`s Medium 
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(DMEM without Phenolred, with L-Glutamine), Fetal Calf Serum  Gold 
(FCS Gold) and DMEM were purchased from PAA Laboratories GmbH, 
Cölbe, Germany. The Kinetic-QCL® Kinetic Chromogenic Assay was 
bought from Lonza AG, Cologne, Germany. 
Nanoparticles. The carboxylated 50 nm Polystyrene nanoparticles were 
from Polysciences Europe GmbH, Eppelheim, Germany. The CeO2 C and 
TiO2 B were synthesized in pyrogenic processes; ZrO2 was synthesized 
and modified with an organic acid in solution. The nanoparticles were 
used as received without purification. The most relevant intrinsic proper-
ties are summarized in Table 2.1. The particle morphology and primary 
particle size are characterized without physiological media by monolayer 
TEM (Figure 2.1). Particle surface chemistry was determined by photoe-
lectron spectroscopy (XPS) and crystallinity by X-Ray diffraction (XRD). 
The experimental details for those methodologies can be found in chapter 
3.3. We find atomic concentrations of oxygen and metal in the ratio 2.2 
(TiO2 B), 2.6 (ZrO2) and 2.0 (CeO2 C). The solubility was determined by 
dispersing 10 mg/ml of the particles in water under stirring for 24h, re-
moving the particles by centrifugation at 40,000 rpm, and finally deter-
mining the ion content in the supernatant by inductively coupled plasma 
optical emission spectroscopy (ICP-OES).  
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Table 2.1. Physico-chemical properties of the used nanoparticles (values 
adopted from [35]). 
Sample 
Chemical com-
position; crys-
tallinity 
Mean pri-
mary parti-
cle size; 
morphology 
Surface 
chemistry 
Organic 
modification 
Water 
solubility 
TiO2 B 
> 99.5 % TiO2 
rutile and ana-
tase, tetragonal 
27 nm 
irregular 
but globu-
lar 
O 58 % 
Ti 26 % 
C 14 % 
N 0.5 % 
Cl 1% 
none 1 ppm 
ZrO2 
ZrO2 
monoclinic 
Baddeleyite, 
tetragonal 
14 nm 
irregular 
but globu-
lar 
O 55 % 
Zr 21 % 
C 24 % 
Cl  0.6 % 
organic acid 190 ppm 
CeO2 C 
 
> 99 % CeO2 C 
Cerianite, cubic 
70 nm 
irregular 
but globu-
lar 
O 53 % 
Ce 26 % 
C 20 % 
Cl  0.6 % 
none <1 ppm 
 
 
Dispersing nanoparticles in different media. Stock solutions contained 
a mass concentration of 1-10 g/L. For this purpose, the nanoparticles 
were weighed into snap-on lid glasses (diameter 20 mm, height 40 mm) 
and covered with 5-6 ml of dispersion medium. A small magnetic stirrer 
(length: 12 mm) was added and the glass covered with a lid. Stock solu-
tions had to be stirred at 900 rpm for 1 hour. Then, aliquots could be 
taken and added to the already stirring dispersion medium to get the fi-
Figure 2.1. Monolayer TEM images of the nanoparticles, showing primary 
particles sizes of a) TiO2 B 21nm; b) ZrO2  14nm; c) CeO2 C 30nm.  
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nal dilution. This dispersion was stirring for 24 h at room temperature 
and 900 rpm before use. If the particles were dispersed in rich media, the 
particles and all other devices had to be sterilized and contamination 
during the dilution step be avoided. Buffers and Media were used as fol-
lows: Millipore® water, phosphate buffer, isotonic phosphate buffer, 
Krebs-Ringer-Buffer, Dulbecco`s Modified Eagle`s Medium (DMEM with-
out Phenolred, with L-Glutamine), Fetal Calf Serum  Gold (FCS Gold) 
with varying concentrations of FCS. 
Size and ζ-Potential measurements via Dynamic light scattering. For 
normal size and ζ-potential measurements, the nanoparticle dispersion 
(concentration 2.5 %) was diluted 1:100 in the dispersion medium and 
then measured with the Zetasizer Nano ZS (Malvern Instruments, Her-
renberg, Germany). Size measurements were performed at 25 °C with an 
equilibration time of 1 min in disposable sizing cuvettes at automatic 
mode. Every measurement was performed 3 times with the automatic at-
tenuator set and the data processed in general purpose mode. For ζ-
potential determination, the model of Smoluchowski was used and the 
automatic measurements (10-100 runs) performed 3 times at a tempera-
ture of 25 °C and an equilibration time of 1 min. The attenuator and volt-
age were selected automatically and the data processed with monomodal 
mode. 
Analytical Ultracentrifugation (AUC). The particle size distribution was 
determined by analytical ultracentrifugation (AUC) of ~500 μL of a test 
substance preparation with 0.1 mg/ml of NPs. At the acceleration of up 
to 300,000 g used in AUC, solutes and nanoparticles sedimented into 
fractions that were separated according to their size in the range 0.5–
100.000 nm. Simultaneous detection by synchronized optics quantified 
the amount and the diameter of each fraction independently [36]. When 
there was a low concentration of nanoparticles in a high-concentration 
protein medium, nanoparticles were easily discerned from sedimenting 
proteins because of their much higher density and resultant faster sedi-
mentation of many orders of magnitude, and because of their higher re-
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fractive index and high turbidity. We used a Beckman model XL ultracen-
trifuge (Beckman Coulter GmbH, Krefeld, Germany) that we modified for 
the online recording of sedimentation with turbidity, interference, and 
Schlieren or ultraviolet (UV) detection [37]. This modification allows the 
use of interference and turbidity optics with a ramped rpm–profile to 
quantify the amounts of ultrafine fraction (diameter <100 nm), fine frac-
tion (100 – 1000 nm), and larger-scale material (>1 µm). 
The evaluation of the AUC raw data incorporated the fractal morphology 
of nanoparticle aggregates and applied the fractional dimension of 2.1 
together with the sedimentation relation as specified in Eq. (6) of the ref-
erence [38]. This value of the fractional dimension has been shown to be 
universal for all reaction-limited colloid aggregates [38, 39]. If in the spe-
cific test substance application preparation the fractional dimension of 
the aggregates were higher (lower), corresponding to a more compact 
(loose) structure of the aggregates, the retrieved particles sizes would 
shift to lower (higher) values. 
The adsorption of BSA onto polymeric particles was quantified in density 
gradient experiments in a Schlieren-optics AUC [37]. Nycodenz was used 
as gradient medium, and the sample was added in 0.5 mg/ml concentra-
tion. It accumulated at the isopycnic point, where its buoyant mass cor-
responded to the local density determined by the local Nycodenz concen-
tration. The Schlieren optics measures the derivative of radial 
concentration dc/dr(r), the meniscus is left, the outer boundary of the 
cell is right, the column height is 1cm. A gaussian distribution of density 
fractions gives a positive-negative modulation of the positive-slope signal 
form the rising concentration of Nycodenz. 
Sterilisation of glasses and nanoparticle dispersion for microbiologi-
cal analyses. 10 ml glasses, lids and magnetic stir bars were washed 
twice with autoclaved, sterile filtered (Millipore GmbH, Schwalbach, Ger-
many) bi-distilled water and once with 70 % ethanol diluted from 100 % 
ethanol with autoclaved, sterile filtered (Millipore®) bi-distilled water. The 
glasses and the magnetic stir bars (5x12mm) were then autoclaved for 
20 min at 134°C and 2.5 bar/vacuum in a Varioklav 135S (H + P Labor-
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technik GmbH, Oberschleißheim, Germany) whereas the lids were stored 
in 70 % ethanol in autoclaved 100 ml Schott bottles. Before use, the lids 
were dried in a laminar air flow and irradiated with UV light for 15‟. A stir 
bar was placed into each glass which was then covered with a dried and 
irradiated lid before determination of the net weight. A small amount of 
TiO2 B or CeO2 C powder (~20 mg) was transferred into a glass under 
laminar air flow and the mass of the powder was determined. An appro-
priate amount of DMEM (10 % FCS) was added to the powder to yield a 
concentration of 3.2 mg/ml. To generate a 3.2 mg/ml dispersion of ZrO2 
(stabilized with an organic acid, 46 % w/v), the original dispersion was 
stirred on a magnetic stirrer for 1 h at 900 rpm and room temperature 
and 417 µl of the original dispersion were then added to 5.683ml of 
DMEM (10 % FCS) in a glass prepared as described above. The disper-
sions were stirred for 1 h at 900 rpm and then diluted 1:10 in DMEM (10 
% FCS). The dilutions were stirred for another 24 h at 900 rpm and room 
temperature.  
Sterilisation of nanoparticles for microbiological analyses. To test the 
suitability of standard cell culture antibiotics and wet antiseptics, parti-
cle dispersions were generated using DMEM containing Penicillin, Strep-
tomycin, and Amphotericin B or 200 mM sodiumazide. Heat sterilization 
was performed in an H+P Varioklav 135S for 20 min at 134 °C and 2.5 
bar/vacuum. A Biobeam 8000 (STS Steuerungstechnik und Strahlen-
schutz GmbH, Braunschweig, Germany) with a 137 Cs γ-ray source was 
used for γ irradiation. 
Microbiological analyses. Microbiological analyses were performed at 
the Institute for medical microbiology at the Münster university hospital. 
Dispersions of ZrO2, TiO2 B, and CeO2 C (320 µg/ml) were tested aerobi-
cally and anaerobically for sterility according standard procedures apply-
ing fluid and solid media under long-term cultivation [40]. 
Determination of endotoxin concentration. The Kinetic-QCL® Kinetic 
Chromogenic Assay (sensitivity range 0.005 EU/ml – 50.0 EU/ml) was 
used to determine endotoxin concentrations. The test was performed ac-
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cording to the manufacturer‟s instructions. The absorption was moni-
tored using the microplate reader NOVOstar (BMG Labtech, Offenburg, 
Germany). Apart from testing pure dispersions of ZrO2, TiO2 B and 
CeO2 C (320 µg/ml), nanoparticle dispersions were mixed with a stand-
ard endotoxin solution (0.25 or 0.5 EU/ml) in order to investigate the in-
fluence of the particles on the enzymatic reaction. The surface modifier of 
ZrO2 was tested likewise. Four endotoxin standards (5-0.05 EU/ml) were 
used to generate a standard curve to calculate endotoxin concentrations. 
Therefore, Trend2k (Thomas Risi Softwaredevelopment, Vilsheim, 
Gemrany) was applied to calculate fifth degree polynomials describing the 
development of absorption of the standards. The y-values (in seconds) of 
the polynomials at x = 0.2 were calculated and used to generate a loga-
rithmic equation describing the relationship between the standard endo-
toxin concentrations and the time after which the absorption had in-
creased by 0.2 units. This equation was used to calculate the endotoxin 
concentrations of the nanoparticle dispersions. Values < 0.005 EU/ml 
were equated with 0 as they lie below the detection limit of the assay. 
 
2.4 Results & Discussion 
Polystyrene nanoparticles. Before studying the specific pitfalls with 
metal oxide NPs, the test systems were established by characterization of 
model NPs (polystyrene NPs from Fluoresbrite, carboxylated, Ø 50 nm; 
c50) in size and ζ-potential via Dynamic Light-Scattering in different dis-
persion media with increasing complexity (Table 2.2). In Millipore® water, 
the hydrodynamic diameters of the particle were 49.5 ± 1.7 nm and had a 
ζ-potential of -64.4 ± 4.2 mV. In phosphate buffer (0.05 M; ionic strength 
0.116 M), and isotonic phosphate buffer (0.05 M; ionic strength 0.154 M) 
the c50 particle showed a slightly higher size of 67 ± 3.5 nm or 57.5 ± 1.7 
nm, respectively. The ζ-potentials increased to -58.6 ± 0.8 mV and to -
51.2 ± 3.9 mV when isotonized. When dispersed in Krebs-Ringer-Buffer 
(KRB), the c50 agglomerated and showed a size of more than 3000 nm. 
Also, the ζ-potential increased nonlinear to -29 ± 1.4 mV (Figure 2.2). 
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Since the presence of Ca2+ ions is a significant difference between phos-
phate buffers and KRB, CaCl2-titrations in water and both phosphate 
buffers were performed and the sizes of the particles at concentrations of 
0-5 mM Ca2+ determined. The experiments revealed the Ca2+ as main fac-
tor in the agglomeration of c50 in KRB. At CaCl2 concentrations from 0.5 
to 2.5 mM Ca2+ (CaCl2 concentration in KRB: 1.4 mM), particles agglom-
erated in all buffers tested (Figure 2.3). 
Addition of bovine serum albumin (1 %) lead to complete deagglomeration 
(hydrodynamic diameter decreased to 70.2 ±1 nm) and a further ζ-
potential increase up to -10.4 ± 2.7 mV (for comparison: 1 % of BSA in 
KRB without particles had a ζ-potential of -5.6 ± 2.7 mV). The slight in-
crease in diameter compared to the values in water and the similar ζ-
potential in relation to the ζ-potential of BSA in KRB without particles 
suggested a protein coating of the particles.  
 
 
Table 2.2: Increasing complexity of the dispersion media used to find the reason 
for agglomeration of the c50 model polystyrene particle in KRB 
 H2O 
PB (pH 
7.4) 
PB, iso-
tonic (pH 
7.4) 
KRB 
KRB +  
1 % al-
bumin 
pH - + + + + 
isotony - - + + + 
[Ca2+] - - - + + 
presence 
of pro-
tein 
- - - - + 
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Figure 2.3. Ca2+-depending size of a carboxylized 50 nm polystyrene particle 
in different dispersion meda. 
 
 
Figure 2.2. Sizes and ζ-potentials of c50 NPs in different dispersion media. a) 
hydrodynamic diameters of the c50 NPs, measured via Dynamic Light Scatter-
ing (DLS) and Analytical Ultracentrifugation (AUC); the black line corresponds 
to the primary particle size. In Milipore water and both phosphate buffers, the 
sizes ranged around 50-70 nm. In KRB, large agglomerates occurred, which 
were not present when dispersing the particles with KRB containing 1 % of 
BSA.  b) ζ-potentials of the particles in the same buffers. 
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To prove this hypothesis, a density gradient ultracentrifugation [36] was 
performed. The density gradient fractionated the sample according to the 
buoyant density and hence was direct evidence of the chemical composi-
tion, but insensitive to diameters. In repeated experiments, no signal at 
the density of pure polystyrene (1.57 g/cm3) was detected, but a strong 
signal at 1.26 ± 0.06 g/cm3, corresponding to composite particles of 
~40/60 BSA/PS (Figure 2.4). The width of the distribution indicated a 
distribution of densities; hence the adsorption was not uniform. The non-
uniform adsorption was reflected also by the significant increase and 
broadening of the particle sedimentation velocities upon mixing with BSA 
(data not shown). From the velocity increase, an adsorption of 20–60 wt% 
BSA on the PS core was deduced, in good agreement with the density 
gradient approach. Finally, the binding of protein onto the carboxylated 
particle surface was monitored by a loss of freely dispersed BSA mono-
mer and dimer as quantified by their characteristic sedimentation coeffi-
Figure 2.4. Density gradient measurement of the density of polystyrene NP 
c50, dispersed in KRB + 1 % BSA. The left margin corresponds to the meniscus 
at a density of 1.07 g/cm3, the right to the boundary of the cell at 1.36 g/cm3, 
i.e. the force is directed to the right. The particles accumulate at their isopyc-
nic point, where their density corresponds to the density of the gradient medi-
um, in this experiment around 1.20 g/cm3. Unprocessed CCD image in the in-
set: The Schlieren-AUC measures dc/dr(r) and a gaussian distribution of 
density fractions induces a positive-to-negative modulation (original) super-
imposed with the positive-slope signal from the rising concentration of the 
gradient medium. (see materials and methods) 
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cients (data not shown).  
Taken together, these data were the first direct and quantitative in-
solution evidence of adsorption of proteins on (polymeric) NPs (Figure 2.4) 
with ensuing dispersing action, as seen by DLS and AUC in excellent 
agreement. (Figure 2.2a). 
It is known that electrostatically stabilized NP dispersions with a ζ-
potential converging to zero become unstable [34, 39]. That is exactly 
what happens when dispersing the c50 in KRB containing 1.4 mM CaCl2: 
the electrostatic stabilization is not sufficient to avoid agglomeration an-
ymore. Presumably, the deprotonated, negatively charged carboxyl 
groups at the particle surface interact directly with the positively charged 
Ca2+-ions. The increase in size of c50 when dispersed in KRB containing 
1 % of BSA was due to covering the particles with albumin. The coating 
of particles with BSA was shown with colloidal gold [41], polymer colloids 
[33, 42] and aluminum hydroxide [43] particles already. The originally 
electro statically stabilized particles can be dispersed in media containing 
Ca2+ via a switch to a steric stabilization by addition of albumine [39]. 
Metal oxide nanoparticles. The results found for model particles were 
then transferred to much less defined metal oxide NPs. In cell culture the 
addition of serum to the culture medium, mostly fetal calf serum (FCS), 
is mandatory for many cell lines to guarantee an ideal cell growth [44]. 
Therefore, FCS replaced BSA as the protein component in the test sys-
tems. Dry CeO2 C and TiO2 B particles (both used as manufactured with-
out any modifications; this condition will be referred to as „naked‟) and 
predispersed ZrO2 (organically modified and stabilized with an organic 
acid with a molecular weight of 180 g/mol) were dispersed in different 
physiological media and Millipore® water to test which medium suits best 
for in vitro assays. The NPs were weighed into a snap-on lid glass, covered 
with the dispersion medium and stirred for 24 h without any ultrasound 
treatment. Particles sedimented immediately in media free of proteins. 
However, dispersions were stable in protein-containing media for the ζ-
potential measurement period. The ζ-potentials of all particles in protein 
containing buffered media were very similar to the ζ-potentials of parti-
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cles in pure buffered media. Particles in ion free water showed completely 
different ζ-potentials (Figure 2.5). 
 
 
 
Figure 2.5. ζ-potential of CeO2 C, TiO2 B and ZrO2 in different dispersion me-
dia. Except in water, the ζ-potentials of the particles are more or less the 
same. No difference can be seen between KRB and DMEM with or without 
addition of proteins, i.e. from this measurement no adsorption of the pro-
teins onto the particle surface can be concluded.  
 
 
The ζ-potential measurements gave no direct evidence for a protein coat-
ing of the inorganic industrial particles tested. However, the stabilization 
of particle dispersions by added proteins indicated a coating. The switch 
of the originally positive ζ-potentials of CeO2 C and ZrO2 in Milipore water 
to negative values in media containing 10 % FCS was in good correlation 
to the findings of Limbach et al., but they postulated that this switch 
leads to agglomeration of CeO2 C and also other metal oxide NPs because 
of a loss of electrostatical stabilization [28]. Contrary to these results a 
correlation of particle size and protein concentration in the dispersions 
was seen in this work (see Figure 2.6). 
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Size characterization constitutes a major pitfall due to the enormous col-
loidal polydispersity [34]. Ultrafine particles (NPs < 100 nm in diameter) 
[45] and agglomerates have to be quantified in a hundredfold excess of 
proteins with 5 nm diameter (BSA monomer) plus salts. The most wide-
spread methods of characterization on the example of TiO2 B in pure FCS 
were cross-checked (Figure 2.6, diamonds). The nominal working range 
of DLS does cover all components, but even after prefiltering (450 nm 
pore size) DLS fails to detect the proteins that constitute 99% of the sam-
ple. The same is true for laser diffraction, whose lower working limit is 
exceeded. TEM images the NPs and agglomerates, but with comparably 
low statistics. Even without particles, we found that drying and/or cryo-
preparation of FCS induces artefacts [34]. Optical AUC [36, 38] is the on-
ly method that detects also the sub-10-nm proteins with correct molar 
masses and concentrations (found in FCS 33mg/ml at 65 kDa  and 120 
kDa (corresponding to 4–5nm), attributed to BSA monomer and dimer), 
but in the ultrafine particle range the turbidity-AUC has its uncertainties 
Figure 2.6. Diameters of CeO2 C (green triangles), TiO2 B (black squares) 
and ZrO2 (red dots) in DMEM with different concentrations of FCS from tur-
bidity-AUC. d50 values represent the weight-average agglomerate size. In 
complete reproductions of preparation and measurement the values scatter 
by ± 30 %. In all cases, the particle size decreases with increasing concen-
tration of FCS, which shows its disagglomerating properties, leading to 
significant fractions of ultrafine particles in the dispersions (lines are 
guides to the eye). Grey diamonds come from inappropriate methods, black 
diamonds show differing results from several valid approaches, all on TiO2 
B in 100% FCS.  
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due to the Mie correction of intensities. X-Ray-AUC needs no such cor-
rection and detects selectively inorganic components, but requires ex-
ceedingly high concentrations of particles (~1%). Note that only accelera-
tions above 1000g enable the detection of ultrafine components in 
sedimentation (fulfilled for X-ray-AUC fast (6000 rpm), not for slow (1500 
rpm)) (Figure 2.6).  
It is beyond the scope of this contribution to settle the size characteriza-
tion issue. The results presented here suggest that DLS, laser diffraction 
and slow-speed sedimentation cannot determine whether an ultrafine 
fraction is present or not. Several valid methods confirm that FCS deag-
glomerates NPs to a significant fraction of ultrafine particles with low en-
ergy input by stirring only, independent from an often used ultrasound 
treatment.  
The deagglomeration scales with the protein content. In Dulbecco's Modi-
fied Eagle's Medium (DMEM), all of the tested NPs were strongly agglom-
erated and no significant fraction of ultra fine particles could be deter-
mined (Figure 2.6). With increasing concentration of FCS, the mean 
particle size distribution (d50) decreased, and a significant effect could be 
seen even in the presence of 5 % FCS. Also, large agglomerates were dis-
integrated, indicated by the declining d90 (data not shown).  
The ZrO2 used was stabilized and coated with an organic acid and well 
dispersible in ion free water, but agglomerated in DMEM, due to a change 
in pH. In 100 % FCS, the dispersion was as good as in pure water (Figure 
2.7a). This behaviour was very similar to the dispersion pattern of car-
boxylated polystyrene particle: well dispersible in water, strong agglomer-
ation in the presence of salts and dispersible again by addition of pro-
teins. The naked TiO2 B particle revealed a different dispersion pattern: 
hardly dispersible in water, wetted but still agglomerated in DMEM (Fig-
ure 2.7b). With increasing FCS-concentration, particles deagglomerated 
and at FCS-concentrations above 40 %, an ultrafine dispersion was 
reached. Two different dispersion patterns are evident: a) the naked NPs 
(CeO2 C, TiO2 B) and b) the particles modified with an organic acid (ZrO2 
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and polystyrene latex). Dispersion patterns seem to depend mostly on the 
particle‟s surface modification, irrespective of the particle‟s bulk material.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has been reported previously that metal oxide NPs mixed with a BSA 
solution showed a uniform ζ-potential, irrespective of their 'naked' chemi-
cal surface modification. This effect was thought to result from a BSA NP 
surface coverage [30]. Aqueous NP suspensions have been stabilized to 
prevent agglomeration by addition of BSA and FCS [31]. No systematic 
study on the effect of protein adsorption on the NP deagglomeration ten-
dency has been published yet. Natural organic matter act as effective 
wetting and dispersing agents for carbon nanotubes, often more effective 
than synthetic head-tail surfactants [27]. The wetting and dispersing ef-
fect of interface-active proteins (among them HSA) has very recently been 
shown to be effective to debundle agglomerated single walled carbon 
nanotubes in aqueous suspension, which was technically a very demand-
ing task before [29]. Similar to model nanoparticles, where direct evi-
dence of both adsorption (Figure 2.6) and ensuing dispersion were pro-
Figure 2.7. Size distribution of a) ZrO2 (stabilized with an organic acid) and 
b) TiO2 (unmodified) by turbidity-AUC. The ZrO2 particle is well dispersible 
in water (yellow line) and strongly agglomerating in the high salt DMEM 
(black line), whereas the TiO2 is hardly dispersible in water, at all. With in-
creasing concentration of FCS, the particle sizes decrease at both particles.   
a) b) 
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vided (Figure 2.5), we identified adsorbed protein functioning as protec-
tion colloids as mechanism for the observed dispersion effect (Figures 2.2 
to 2.4) [39]. Especially albumines are interface active and show at least 
five different binding sites for an entire variety of molecules (inorganic 
minerals, proteins, polar organic molecules, fats, and chiral centers) [46]. 
These findings are in agreement with and complementary to the previous 
reports of protein adsorption to NPs and carbon nanotubes. 
Microbiological aspects. The dispersion of NPs in buffered solutions of 
proteins and nutrition allows the growth of contaminating microorgan-
isms. Since these organisms as bacteria, yeast or other fungi and their 
metabolism products interfere with most standard toxicity test systems, 
NP preparations have to be sterilized.  
For the optimization of the sterilization procedure the germ load of the 
used industrially produced and processed NPs was analyzed. Dispersions 
of ZrO2, TiO2 B, and CeO2 C were tested aerobically and anaerobically for 
sterility according standard procedures applying fluid and solid media 
under long-term cultivation [40]. The prominent bacteria identified were 
Micrococcus luteus [47, 48] and Bacillus sp. [48, 49]. M. luteus is a Gram 
positive, spherical, saprotrophic spore-forming bacterium that belongs to 
the Micrococcaceae. [50]. Bacteria of the genus Bacillus are Gram-
positive, rod-shaped, spore-forming, and are either facultative or obligate 
anaerobes.  
Due to the presence of microorganisms in the NPs analysed, different 
standard methods for sterilization of cell culture materials to aliquots of 
dispersed ZrO2, or TiO2 B and CeO2 C were applied. In order to reduce 
the microorganism burden of the particles, the addition of antibiot-
ics/antimycotics, chemical sterilisation (sodiumazide, NaN3), heat sterili-
sation (134 °C, 2,5 bar), and sterilisation by ionizing irradiation (30 Gy) 
was chosen.  The sterilisation method should be effective to kill microor-
ganisms without altering NP properties and without influencing the bio-
logical test systems. 
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NPs sterilized with the various methods were dispersed in cell culture 
medium and tested for contaminating microorganisms as described 
above. According to these standardized analyses, only γ irradiation was 
capable of eliminating all microorganisms identified in dispersions of un-
treated NPs. It has been shown that spores are often more resistant to 
γ irradiation than metabolically active bacteria [51], however, the under-
lying mechanism is still unclear [52]. The amount of endospores and the 
general level of contamination in the set-up appear to be sufficiently low 
to be eliminated by γ irradiation. 
As γ rays have the capacity to ionise atoms, the effect of irradiation on 
nanomaterial properties was characterized. Irradiated and untreated dis-
persed ZrO2, or TiO2 and CeO2 C powders were analysed with regard to 
surface chemistry (ζ-potential and X-ray Photoelectron Spectroscopy, 
XPS), bulk structure (X-ray diffraction, XRD) and dispersion behaviour 
(AUC). None of the four methods detected any significant change after 
irradiation, hence γ-rays can serve as standard sterilisation procedure 
since neither surface nor the structure of our particles was altered. 
Beside microorganism contamination itself test systems can also be af-
fected by endotoxins, biologically highly active bacterial molecules often 
present in materials after a bacterial contamination. In 1894, endotoxin 
was first described as a heat-stable toxic substance that was released 
upon disruption of microbial envelopes [53]. Today, endotoxin is widely 
defined as component of the outer cell membrane of Gram negative bac-
teria being made up by lipopolysaccharides with lipid A being the bioac-
tive component [54]. Inoue et al. (2006) have reported that endotoxins 
aggravate the inflammatory effect of carbon NPs in mice when applied 
simultaneously [55], on the one hand while nanometre sized TiO2 B has 
been shown to adsorb endotoxins and cause proinflammatory reactions 
[56]. Furthermore, the determination of endotoxin concentration is a 
standard procedure in characterizing particulate matter or dust when 
studying health risks resulting from environmental [57] and work-place 
exposure.  
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To determine the endotoxin concentration of dispersed and powder NPs 
the Limulus amebocyte lysate (LAL) test (Kinetic-QCL® Kinetic Chromo-
genic Assay; Lonza) was used. Dispersions of ZrO2, TiO2, and CeO2 C (32 
µg/ml) were first tested with and without added standard endotoxin con-
centrations to determine the influence of the nanomaterial on the enzy-
matic assay. The ZrO2 organic surface modifier was tested likewise. 
Nanoparticles reduced the measured endotoxin concentrations by more 
than 50% (TiO2 B, CeO2 C) or about 70% (ZrO2, organically modified). As 
the particles do not decrease the measured absorption at 405 nm, this 
effect must be due to a partially inhibition of the enzymatic reaction (Fig-
ure 2.8). Also the ZrO2 surface modifier (OM) contributes to the effect on 
the endotoxin test, as an amount of OM diluted in cell culture media 
equivalent to the amount present in the tested particle dispersions com-
pletely abolishes a detectable reaction. However, the particle bound sur-
face modifier showed a minor effect on the endotoxin test system. 
According to Friberg (1987), the average endotoxin concentration in hu-
man plasma is 6 pg/ml (0,07 EU/ml) which is half of the theoretical en-
dotoxin concentration during a pyrogen reaction [58]. The endotoxin con-
centration measured in the particle dispersions is well below the 
detection limit of the assay (0,005 EU/ml ≙ 0,5 pg/ml). Even taking into 
account the inhibitory effect of nanoparticles on the test system the en-
dotoxin concentrations of NP dispersions were below a critical limit. This 
result was expected as we did not detect any gram- bacteria in the parti-
cle dispersions. 
Overall, we have identified γ irradiation as method of choice to efficiently 
sterilize dispersed and powder NPs for the use in physiological media 
without changing material properties and without disturbing the in vitro 
test systems. 
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Furthermore, our data show that particles should be tested for endotox-
ins for in vivo and in vitro testing to prevent endotoxin dependent results 
of toxicity tests. The applied Kinetic-QCL endotoxin assay is suitable for 
measurement of NPs endotoxin concentration, however, the influence of 
NPs and possible surface modifiers on test results of the endotoxin assay 
needs to be considered when designing assays controls and interpreting 
absorption data. Based on these data and the relevant literature the use 
of NPs is recommended only if the endotoxin contamination is below 
0,5 pg/ml, the detection limit of the assay.  
The three nanomaterials tested in the frame of this study do not contain 
endotoxin in an extent detectable by the assay and exceeding the average 
concentration in human plasma and may therefore be used for in vivo 
and in vitro testing. 
 
Figure 2.8. Influence of CeO2 C, TiO2 B and ZrO2 (org. mod.) dispersions on 
the Kinetic QCL®-Assay; CeO2, TiO2, ZrO2 (org. mod.) reduce the reaction 
rate to about one half to one third of the standard, the organic modifier 
(OM) applied to ZrO2 particles completely inhibits the reaction when used in 
a concentration equivalent to the concentration in the ZrO2 dispersion. 1 
EU/ml ≙ 0.1 ng/ml (E. coli 055:B05 endotoxin) 
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2.5 Conclusion 
Many facets of preparation of nanoparticle dispersions have to be taken 
into account before physiological assays with NPs can be correctly inter-
preted. It is not sufficient to characterize the intrinsic properties of the 
nanomaterial – such as chemical composition and crystallinity, primary 
particle size and morphology, surface chemistry and charge, organic 
modification and water solubility. 
The necessary information beyond intrinsic properties that one will need 
when working with NPs in physiological media is summarized in a check-
list: 
Dispersion issues  
 dispersion protocol 
 agglomerate size distribution and agglomeration state 
 ζ-potential  
 wettability and tendency to agglomerate/deagglomerate due to ad-
sorption of solvent compounds 
 adsorption of solvent compounds with possible influence on pas-
sivation, solubility, recognition. 
Microbiological issues 
 sterility 
 endotoxin concentration 
 endotoxin test reliability 
 
By application of these topics characterized dispersions of particles for in 
vitro toxicity tests become available and reliable experiments can be per-
formed. 
To summarize the results, the drastic dispersing activity of fetal calf se-
rum mixed with various types (polymer and metal oxide) of NPs that are 
either naked or organically modified was quantified. In pure serum, NPs 
were deagglomerated down to significantly nanosized dispersions, pre-
sumably by adsorption of proteins functioning as protection colloids. To 
complement this result, the first in-solution quantitative evidence of ad-
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sorption of proteins on (polymeric) NPs with ensuing dispersing action 
was reported, in excellent agreement of several fractionating and integral 
methods.  
Furthermore, evidence of inadvertent microbial contamination of stand-
ard NP test substances was provided, a source of false interpretation of 
supposed nano-effects. The γ irradiation as appropriate sterilization 
treatment was identified and used for further cell related testing. A com-
prehensive but feasible checklist to guarantee reproducible and reliable 
in vitro studies with inorganic NPs was proposed.  
The recommendations expressed here are based on experimental findings 
and have implications for cell culture nanotoxicology. Do observed effects 
truly arise from the particle itself? With the above checklist, the pitfalls 
arising when dispersing NPs in physiological media to use them in in vitro 
assays can be overcome. 
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3 Intrinsic physico-chemical properties of CeO2 nano-
particles do not mirror their biorelevant protein ad-
sorption 
 
The data presented in this chapter have been submitted partially as a 
research article in the journal ACS Nano: 
 
Jens Schaefer, Christine Schulze, Elena E.J. Marxer, Ulrich F. Schaefer, 
Wendel Wohlleben, Udo Bakowsky, Claus-Michael Lehr: Intrinsic physi-
co-chemical properties of CeO2 nanoparticles do not mirror their bio-
relevant protein adsorption, ACS Nano, submitted 
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3.1  Abstract 
As engineered nanomaterials like CeO2 particles reveal novel properties 
compared to the bulk material, also their toxicity is a major issue. Once 
they entered the body, the can interact with the physiological surround-
ings, i.e. also with proteins. This particle-protein interaction might lead 
to altered reactions concerning the particles, influencing their bio-
persistence in the body. Hence, the investigation of protein adsorption 
onto those particles is of great importance. We investigated and com-
pared the protein adsorption of Bovine Serum Albumin to three CeO2 na-
noparticles with only slightly different physico-chemical properties with 
Atomic Force Spectroscopy, Analytical Ultracentrifugation and BCA-
assay. All adsorption processes could be fitted with a sigmoidal mathe-
matic model, revealing differences in half-maximal adsorption for espe-
cially one of the three particles. Clearly, particles of the same bulk mate-
rial do not necessarily reveal the same adsorption pattern for proteins, 
and the state of agglomeration must be taken into account to interpret 
the results correctly. We also showed that the protein might alter its 
shape during adsorption process specifically for the different particles 
tested. We conclude that even small differences concerning particle prop-
erties can lead to different protein adsorption and hence might provoke 
different reactions in the body. This means that testing of one particle of 
a bulk material as reference is not enough to determine the potential tox-
icity of nanomaterials.  
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3.2 Introduction 
After proof of protein adsorption for a model particle and strong indica-
tions for protein adsorption on metal oxide particles, further investiga-
tions were performed to prove protein-particle interaction also for the 
metal oxide particles.  
Only a small fraction of 1 % or less of an inhaled nanomaterial dose 
translocates into the blood stream  [5], but due to bio-persistence issues 
that fraction also must be considered. Biopersistence may be influenced 
by protein adsorption of serum albumin after uptake into the blood sys-
tem, and therefore this has to be investigated in the evaluation of toxic 
effects of nanoparticles. 
The Dawson group has pioneered structure-property-relationships in 
protein coronas during the last few years [59, 60], and the biophysics of 
adsorbed proteins has been reviewed recently [61]. The majority of the 
few studies on metal oxides found adsorption of albumins (in serum) or 
humic acid (in soil), ensuing increased dispersibility [61, 62]. Cedervall et 
al. investigated the protein corona from serum, albumin and fibrinogen 
on polymeric nanoparticles using methods like microcalorimetry and sur-
face plasmon resonance technique [33]. Recently Nienhaus and col-
leagues studied the adsorption of albumin in great detail, including 
on/off rates, adsorption affinity and monolayer saturation on inorganic 
fluorescent nanoparticles, using fluorescence correlation spectroscopy 
[63]. That match of material and method was powerful because it exploit-
ed the specific fluorescence properties of bespoke core-shell nanoparti-
cles, but in general it is not applicable to industrially relevant nano-
materials.  
Therefore, universally applicable methods were chosen and the extent of 
protein adsorption from Fetal Calf Serum (FCS) and from the dominating 
Bovine Serum Albumine (BSA) as the trigger of biokinetics and recogni-
tion with ensuing toxic effects were investigated intensively. Atomic Force 
Microscopy (AFM) was perforemd to directly analyze protein-particle in-
teractions, as well as the Bicinchoninic Acid (BCA) protein quantification 
assay as an indirect method or Analytical Ultracentrifugation (AUC) to 
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examine the level of agglomeration correlated with the protein corona. We 
concentrated on three CeO2 nanoparticles with very similar physico-
chemical characteristics to see if those traits correlate to a specific pro-
tein adsorption pattern. 
CeO2 nanoparticles (CeO2 NPs) are marketed as oxidative catalysts in 
self-cleaning surfaces in ovens [64], are being field-tested as catalytic die-
sel fuel additives [65] and find application as abrasive for chemical-
mechanical polishing in electronic chip wafer production. The effect of 
CeO2 particles from e.g. diesel fuel or from abrasion of CeO2 containing 
coatings exposed to the environment was recently analyzed by van 
Hoecke et al. [66]. They investigated three different sizes (14, 20 and 29 
nm) of CeO2 particles in different aquatic toxicity tests. The differences in 
toxicity could not be explained by a direct effect of dissolved Ce-ions or 
CeO2 nanoparticles uptake or by physical effects such as light restriction. 
Additionally they found that the particle properties - especially the higher 
surface area of smaller particles - have an influence on the toxicity of 
CeO2 NPs.  
 
3.3 Materials & Methods 
Materials. Phenyltrimethoxysilane (Dynasylan® 9165) and 3-
aminopropyl-triethoxysilane (Dynasylan® AMEO) were a gift from De-
gussa GmbH, Düsseldorf, Germany. N,N-Diisopropylethylamine, and Cy-
anuric Chloride were purchased from Sigma-Aldrich Chemie GmbH, Mu-
nich, Germany. Trichloromethane and methanol were purchased from 
Carl Roth GmbH + Co. KG, Karlsruhe, Germany. Water was double dis-
tilled prior to use. AFM tips CSC 37/noAl and NSC16/AlBS were pur-
chased from Micromasch, Estonia. The BCA-Kit (Bicinchoninic Acid Kit 
for Protein Determination) and all Bovine Serum Albumin derivatives 
(Bovine Serum Albumin, purity 96 %, Bovine Serum Albumin, purity 
99 %, Bovine Serum Albumin isothiocyanate conjugate) were purchased 
from Sigma Aldrich, Fetal Bovine Serum Gold came from PAA Laborato-
ries GmbH, Cölbe, Germany. 
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Physicochemical characterisation of particles. The hydrodynamic di-
ameters of metal oxide nanoparticles were determined by Dynamic Light 
Scattering (DLS) using a Zetasizer Nano ZS from Malvern Instruments 
(Herrenberg, Germany) equipped with a 10 mW HeNe laser at a wave-
length of 633 nm at 25°C, essentially as described previously [67]. Scat-
tered light was detected at a 173° angle with laser attenuation and 
measurement position adjusted automatically by the Malvern software. 
Values given are the means +/- standard deviation of three independent 
experiments with each experiment including three measurements of the 
same sample with at least 10 runs each, as determined by the zetasizer. 
The ζ-potential of the nanoparticles was determined by Laser Doppler 
Electrophoresis (LDE) using a folded capillary electrophoresis cell of the 
Zetasizer Nano ZS at 25°C, the light signal detected at a 17° angle. The 
average value was calculated with the data of three times 10 runs +/- 
standard deviation. 
TEM-imaging. A carbon coated 300 mesh tem grid was dipped into a 
dispersion with a concentration of 0,1 mg/ml in isopropanol of the CeO2 
particles. The crystal structure and crystalline appearance was visualized 
using TEM-imaging on a Jeol JEM-3010 TEM (Jeol Ltd., Tokyo, Japan) 
with 300.000 V. 
XRD crystallinity measurement. Crystallinity was determined by X-ray 
diffraction (XRD). The intensity of the diffracted x-ray beam was recorded 
by a D8 Advance (Fa. Bruker/AXS) as a function of the diffraction angle 
(2° < 2θ < 150°). Quantitative phase analysis was performed using 
Rietveld refinement.  
XPS detection of particle impurities and surface modifications. Im-
purities and surface modification were determined by X-ray photoelectron 
spectroscopy (XPS) with a Phi XPS 5500 system with 300 W monochro-
matic Al- K alpha radiation, pass energy for surveys 117 eV (measure-
ment time of 45 min), detailed spectra at 23.5 eV (measurement time of 6 
min). Evaluation was performed by CasaXPS 2.3.15, based on the Phi 
standard-sensitivity factors, with Shirley background subtraction and 
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peak shape fits as sum of 90 % Gaussian and 10 % Lorentzian. Infor-
mation depth is limited to the surface 10 nm of the material. We per-
formed two measurements per sample, each integrating over 0.5 mm2. 
The results in % are derived from relative concentration of elements and 
their chemical bonds from line shape analyses. 
TOF-SIMS characterization of particles. Static TOF-SIMS spectra were 
recorded using a TOF-SIMS V spectrometer (Iontof GmbH, Germany). A 
pulsed mass-filtered primary ion beam of 25 keV singly charged bismuth 
(Bi+) was used. This primary ion beam, resulting in a spot size of typically 
5 µm on the sample surface, was raster scanned over an area of 250 x 
250 µm to record spectra of positive and negative secondary ions. The 
rastered area integrates over more than 106 particles. The primary ion 
dose density was always kept well below 10-12 ions cm-² and thus in the 
static SIMS regime. To prevent charging of the sample surface, a low-
electron energy flood gun was used. The sample particle sediments were 
prepared for SIMS analysis by their placing on clean silicon wafers. On 
the thus prepared sample positions, no silicon wafer secondary ion mass 
signal could be detected any more, confirming that the sample layer 
thickness well exceeded the SIMS information depth of typically 1-3 nm. 
Contact angel measurement. A thin planarized nanoparticle film of 
1mm thickness was immobilized with a 100µm thick glue film on a PTFE-
foil. After removal of the non immobilized powder the sample was treated 
with filtered nitrogen. The contact angles were measured with drops of 
water, formamide and diiodomethane. The drops were imaged onto a 
CCD and contact angles were extracted by standardized software. 
AFM measurements. AFM tip calibration. AFM tips (CSC 37/noAl, Mi-
cromasch, Estonia) were mounted to an atomic force microscope (Nan-
owizard®, JPK Instruments, Berlin, Germany). A force spectroscopy ex-
periment was performed on purified glass to determine the sensitivity of 
the setup. For this, glass was presumed to be not indentable. The spring 
constants of the AFM tips were determined using the built-in algorithm 
which relies on a method described by Hutter et al. [68]. 
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AFM tip modification. To remove production residues and contaminations, 
AFM tips were precleaned as described by Hinterdorfer et al. [69]. Briefly, 
they were consecutively incubated in peroxymonosulfuric acid and tri-
chloromethane and dried in a dry air flow. Besides the cleaning effect, 
this method results in an enrichment of free silanol groups at the surface 
of the AFM tip. These silanol groups were used to facilitate silanization. 
First, a layer of Dynasylan 9165® was attached to the AFM tip by incuba-
tion in an organic solution of the silane (20 µL / ml trichloromethane) for 
30 min. Subsequently, the AFM tips were washed by dipping them into 
trichloromethane, methanol and water, consecutively. After this, the apex 
of the AFM tip was silanized with Dynasylan AMEO by 30 min incubation 
of the tips in an organic solution of the silane (20 µL / ml trichloro-
methane). This was followed by washing the tips in trichloromethane, 
methanol and water, consecutively. AFM tips were heated to 105 °C for 
1 h in a cabinet heater. Subsequently, the AFM tips were incubated in a 
solution of cyanuric chloride (1 mg/ml trichloromethane) containing 
10 µL N,N-Diisopropylethylamine for 2 h and washed by dipping them 
into trichloromethane and water. To attach BSA to the AFM tips, the pre-
treated tips were incubated in an aqueous BSA solution (10mg/ml) for 
12 h and afterwards washed with water. 
As aromatic silane layers have been reported to be hydrophilic enough 
not to show repulsion when approached to a surface [70], Dynasylan 
9165® was used to inactivate the side faces of the AFM tip. After remov-
ing the inactive a layer of Dynasylan AMEO® was applied to the cleaned 
apex, facilitating covalent coupling of the protein to the AFM tip. 
Particle-protein interaction by atomic force spectroscopy. In an 
atomic force spectroscopy experiment, forces are determined as deflection 
(d) of the cantilever. With the spring constant (kc) of the cantilever given, 
this applied force (Fadh) can be calculated from the detected deflection by 
Hooke‟s law (equation 1) [71]. For this, the exact determination of the 
spring constant and sensitivity of the cantilever, to which the AFM tip is 
mounted, are crucial prerequisites for reliable force spectroscopy experi-
ments. For both, there is a proportional relation to the value of the force 
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measured in an experiment [72]. First, the sensitivity of the setup was 
determined three times. To determine the spring constant, the mean val-
ue of these experiments was used. Spring constants were determined 
three times for each tip and were all within the range of the manufactur-
er‟s specifications (SD<10 %). Prior to each experiment, the AFM sensitiv-
ity was determined again, because every change in the setup (e.g. posi-
tion of the Laser on the backside of the cantilever) may change the 
sensitivity. 
 
dkF cadh *  
Equation 1. Hooke’s law; Fadh= force; kc= spring constant; d= deflection 
 
For each experiment a drop of the particle dispersion, pre-treated in a 
bath sonicator for 3 min, was dried onto a glass slide resulting in a thin 
homogeneous film of the particles. Films were visualized using 
NSC16/AlBS AFM tips in intermittent contact (air) mode. 
In each experiment 64 adhesion measurements were performed on an 
area of 4 µm² with 0.5µm z-length and a retract time of about 0.5 s. The 
experiments were done five times.  
From these adhesion measurements the work of adhesion (Wadh) was cal-
culated according to [73] using the formula: 
 
R
F
W adhA
**2
*3

  
Equation 2. Work of adhesion,  Fadh = force; R = tip radius 
 
According to the JKR (Johnson, Kendall, Roberts) theory, R is the radius 
of the hemispherical point of contact. After each experiment the tip ap-
pearance was checked for dramatic changes. Using the formula: 
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W
  
Equation 3. Surface free energy; Work of adhesion = Wadh ; 2=surface free energy of 
tip 
 
the surface free energy (1) was calculated subsequently. Regarding to 
[73, 74] the surface free energy of the silicon tip determined using the 
contact angle technique range from approximately 41 mJm-2 to 43 mJm-
2. In this study the value of the surface free energy of the silicon tips (2) 
was fixed to 42 mJm-2. The indentation of the particle deformation was 
calculated from the differences in the slope of the force-distance ap-
proach curve between glass as reference and the sample surface. 
Agglomeration control by Analytical Ultracentrifugation (AUC). The 
particle size distribution was determined by analytical ultracentrifugation 
(AUC) of ~500μL of the test dispersion with a mass ratio of nanomaterial: 
FCS proteins = 2:1.  
Simultaneous detection by synchronized interference optics (Beckmann, 
model XLI) quantified the amount and the diameter of each fraction inde-
pendently from 1 nm up to several microns diameter [36, 75]. We can 
thus successively quantify in a single measurement the protein content, 
the protein molar mass, the nanomaterial content, and the nanomaterial 
state of agglomeration. When the retrieved concentration of proteins is 
less than 100 wt% at the expected molar mass, we assume that the re-
maining proteins have adsorbed to a particulate surface. When the re-
trieved concentration of nanomaterial is less than 100 wt% in the meas-
urement interval, we assume that the remainder has agglomerated. The 
evaluation of the AUC raw data incorporated the loose packing of nano-
particle agglomerates by assigning to them a fractional dimension and 
using the fractal agglomerate sedimentation relation as specified in equa-
tion (6) of the reference [38]. We used a value of 2.1 for the fractional di-
mension, which is universal for the morphology of agglomerates from re-
action limited colloidal association (RLCA, i.e. reversible agglomeration) 
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[38, 39]. A fractional dimension of 3 describes solid spheres, and is em-
ployed e.g. in routine DLS or PCCS evaluation, but is obviously wrong for 
agglomerates. The tabulated material's constant of refractive index allows 
the interference optics to linearly direct quantify the fraction that is dis-
persed to diameters below 100 nm in the actual test preparation, with 
the full size distributions. The value for the nanodispersed fraction is re-
garded as an upper limit, judging from the comparison of size determina-
tion methods with different physical measurement principles (chapter 2).  
Determination of protein adsorption onto metal oxide nanopar-
ticles indirectly via BCA-assay. Nanoparticles were dispersed with 2 ml 
of a corresponding protein solution (purified water with Bovine Serum 
Albumin, purity 96 %, Bovine Serum Albumin, purity 99 %, Bovine Se-
rum Albumin isothiocyanate conjugate, or Fetal Bovine Serum Gold), 
leading to particle-protein ratios from 1:10 up to 100:1 (whereas not all 
ratios were tested for all protein solutions used). The resulting disper-
sions were stirred at room temperature for 1 h at 300 rpm, transferred 
into Eppendorf tubes and centrifuged at 23000 g for 45 min and 10 °C in 
a Hettich Universal 30 RF with rotor E1175 (Hettich Lab Technology, 
Tuttlingen, Germany). Afterwards, the supernatants were used for BCA-
assay as described in the manual. A calibration curve with BSA (96 % 
purity) was prepared and the linear equation was calculated after sub-
tracting the background noise (deionized water) to quantify the amount of 
protein in the supernatants. The resulting protein concentrations in the 
supernatants were subtracted from the original concentration and related 
to the negative control (centrifuged protein solution without particles). 
The protein concentration of the particle pellets could not be detected 
due to interactions of the particles with the test principle. Centrifugation 
of BSA/FCS solutions with the same protocol did not change the protein 
concentrations in the supernatant.  
Sigmoidal fitting and determination of half-max values from the ad-
sorption data. The protein adsorption data from BCA-assay were plotted 
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against the different particle-protein ratios (w/w) used and fitted with a 
heuristic sigmoidal model with the equation (equation 4): 
 
pxx
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)(log
12
1
0101
 
Equation 4. sigmoidal fitting function 
 
whereas A1 is the initial value, A2 the maximum of adsorption and x0 
equals to mass ratios at half-max adsorption.  As the adsorption tends to 
100 % with increasing particle-protein relation, A2 was set and fixed at a 
value of 100 % and A1 at a value of 0 %, the hillslope p, which is corre-
sponding to the steepness of the curve, was kept variable. For the fits 
containing of 20 points set between A1 and A2, left and right margin was 
set to 0 and 20 fit iterations were performed. From these sigmoidal fits, 
half-max values were read out. As the AUC data were performed only 
once due to the high costs and efforts, an error-related weighting of the 
data was disclaimed. All calculations were performed with the computer 
program Origin 6.0 (Microcal, Freiburg, Germany). 
 
3.4 Results & Discussion 
Physicochemical characterisation of particles. Intrinsic properties of 
the materials as pristine powder are essential to interpret the protein ad-
sorption patterns in suspension. The results of the physicochemical 
characterization of the investigated particles are summarized in Table 
3.1.  
Visualization of CeO2 particles was performed using AFM and TEM. The 
formulations tend to form aggregates as can be seen in figure 3.1. TEM 
images show square-cut crystalline particles for all batches. In contrast 
to particle sizes of about 20 nm in TEM images, AFM measurements re-
sult in primary particle diameters of 87 nm for CeO2 B and C and 98 nm 
for CeO2 A. 
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Performance of XRD revealed additional Cl for CeO2 C for the otherwise 
very uniform particles. The particle surfaces also show no striking differ-
ences, only CeO2 C shows an additional Li peak according to SIMS meas-
urements. 
Since adsorption should be governed by surface energy and polarity, we 
compared contact angles of a thin planarized powder film with drops of 
water, formamide and diiodomethane. The drops were imaged onto a 
CCD and contact angles were extracted by standardized software. After 
Owens-Wendt evaluation, all samples are hydrophilic, with total surface 
energies of 72.5 mN/m, 71.0 mN/m and 69.1 mN/m for CeO2 A, B and C 
respectively. The disperse part of the surface energy (related to unspecific 
van-derWaals interactions) is lowest for CeO2 C with 40.6 mN/m, against 
41.1 mN/m and 42.3 mN/m for CeO2 A and B.  
To determine ζ-potential and the particle diameter with DLS, nanoparti-
cles were dispersed in double distilled water with a concentration of 
10mg/ml and incubated for 30 min in an ultrasonic water bath at room 
temperature. Sonication leads to a slight reduction of agglomeration of 
CeO2 particles, with PDIs in the range of 0.2 to 0.3. The sizes of the dif-
ferent particles measured with DLS range from 170 nm for CeO2 C to 190 
nm for CeO2 B. The ζ-potentials of all particles are positive with values of 
about +40 mV and comparable values to the manufacturer‟s reference 
data [35]. The pH of the particle dispersions in double distilled water was 
measured to be 5.9 for CeO2 A/ CeO2 C and 6.2 for CeO2 B. 
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Table 3.1. Physical characterization of the tested nanoparticles with Dynamic Light Scattering (DLS), Atomic Force Mi-
croscopy (AFM) and laser Doppler Electrophoresis (LDE) (XRD, XPS, pH and BET surface data were adopted from [35]). 
 
 
 
particle 
 
AFM di-
ameter  
SD [nm] 
TEM 
diame-
ter  SD 
[nm] 
XRD 
crystal-
line 
phase & 
purity 
XPS Sur-
face 
chemis-
try [at%] 
SIMS Surface 
organic con-
taminations 
BET 
surface 
[m²/g] 
[35]  
DLS 
diame-
ter  SD 
[nm] 
(PDI) * 
 
Surface ener-
gy [mN/m] 
(Disperse + 
polar parts) 
pH* ζ-
potential 
 SD 
[mV] * 
 
CeO2 A 97.5  
56.1 
11.6  
5.6 
>99.97 % 
purity, 
cubic 
O 57 
Ce 25 
C 18 
Cerium-oxide-
cluster, Na, 
organics 
63 180.8  
3.0 
(0.257) 
72.5  
(41.4 + 31.1) 
5.9 40.9  
1.7 
CeO2 B 87.0  
49.7 
22.6  
5.7 
>99.97 % 
purity, 
cubic 
O 56 
Ce 22 
C 22 
Cerium-oxide-
cluster, Na, 
organics 
44 189.2  
1.4 
(0.225) 
71.0  
(42.3 + 28.7) 
6.2 38.3  
4.8 
CeO2 C 87.0  
39.7 
22.5  
7.6 
>99 % 
purity, 
Cerianite, 
cubic 
O 53  
Ce 26  
C 20  
Cl 0.6  
Cerium-oxide-
cluster, Na, 
organics, Li 
33 170.4  
2.1 
(0.170) 
69.1  
(40.6 + 28.5) 
5.9 31.5  
3.5 
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Figure 3.1. AFM and TEM images: A) amplitude image (4x4) of CeO2 A parti-
cles; B) amplitude image (2x2) of CeO2 B particles; C) amplitude image 
(2x2) of CeO2 C particles; D) TEM image 25.000 x magnification (300.000 V) 
of CeO2 A particles; E) TEM image 25.000x magnification  of CeO2 B particles 
and F) TEM image 25.000x magnification of CeO2 C particles 
 
 
Indirect measurement of protein adsorption with BCA-assay.  
Different nanoparticle-protein relations lead to very different amounts of 
adsorbed protein: the higher the nanoparticle concentration in relation to 
the proteins, the higher the amount of protein adsorbed. Following incu-
bation and removal of particles and adsorbed corona, the remaining 
(non-adsorbed) protein fraction in the supernatant was quantified a) by a 
protein-binding assay (BCA) and b) by mass-selective detection of BSA 
(AUC). 
a) Plotting the amount of adsorbed protein from BCA-assay of superna-
tants to the nanoparticle-protein ratio leads to a sigmoid pattern for all 
particles tested (Figure 3.2). The adsorption isotherms for CeO2 A and B 
are very similar, but CeO2 C differs: The isotherms are shifted and higher 
particle/protein ratios are required to adsorb all proteins from BSA solu-
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tion or FCS than for the other particles. This trend is more prominent for 
the adsorption of proteins from FCS.  
By analyzing the sigmoid fits derived from BCA-assay with BSA, half-max 
values from 3.4 ± 0.3 up to 6.7 ± 0.3 could be calculated. As those values 
correspond to the particle-protein ratio at which 50 % of BSA is ad-
sorbed, a low number means high protein affinity (see Table 3.2). Within 
this series the different types of CeO2 show different affinity to BSA or 
protein from FCS, respectively, (see Figure 3.2) in descending order: from 
CeO2 A, CeO2 B to CeO2 C.  
b) The similarity of CeO2 A and B is confirmed when we quantify the non-
adsorbed BSA in the supernatant from interference detection during ana-
lytical ultracentrifugation (AUC). Again, sigmoid isotherms describe well 
the data, but quantitative half-max values nanoparticle-protein ratios 
disagree for especially CeO2 C (Figure 3.2c). Note that BCA integrates all 
proteins in FCS-solution or BSA-solution, whereas AUC-measurements 
were performed with FCS solution, but only the mass-selected fraction 
60–80 kDa and 100–140 kDa (assumed to represent BSA) was quantified. 
For CeO2 A and CeO2 B, the adsorbed BSA from FCS-solution (by AUC) 
agrees excellently with the adsorbed proteins in FCS-solution (by BCA-
assay). Significantly fewer nanoparticles are required to deplete BSA from 
BSA-solution than from FCS-solution, since the adsorption isotherm is 
shifted to roughly 60% lower nanoparticle/protein values. 
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Figure 3.2. Adsorption isotherms for the different CeO2 nanoparticles: a) ad-
sorption of BSA from pure BSA solution from BCA-assay, b) overall protein 
adsorption from FCS solution from BCA-assay, c) adsorption of BSA from FCS 
solution, derived from AUC. 
 
 
Table 3.2. Mass ratios at half-max for the adsorption of BSA and protein 
from FCS, gained by sigmoidal fitting of the data derived from BCA-assay 
and AUC (see figure 3.2). As these values correspond to particle-protein ra-
tios, a high value means low particle-protein interaction (R2 > 0.97 for all 
particles tested). 
 CeO2 A CeO2 B CeO2 C 
half-max BSA from BCA-
assay [mg/mg] 
3.4  ± 0.3 4.2  ± 0.2 6.7  ± 0.3 
Half-max FCS from BCA-
assay [mg/mg] 
6.1 ± 0.3 10.3 ± 1 22.8 ± 2.8 
half-max BSA from AUC  
[mg/mg] 
6.3 ± 0.4 10 ± 3.8 2.5 ± 0.8 
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To compare the adsorption of different BSA derivatives and FCS, adsorp-
tion experiments with highly purified (BSA 99 %) and fluorescence la-
beled BSA (FITC-BSA) at a particle-protein ratio of 10:1 was performed 
(Figure 3.3). The protein adsorption of CeO2 A and CeO2 B differed signif-
icantly from that of CeO2 C for FITC-BSA and FCS.  In contrast, the ad-
sorption of BSA 96 % and BSA 99 % was statistically equal for all parti-
cles tested. Protein-particle interaction for FCS proteins was significantly 
different for all particles tested. As the highly purified BSA 99 % does not 
differ significantly from the adsorption of BSA 96 %, a protein adsorption 
mediated by impurities cannot be demonstrated, although the adsorption 
for the highly purified BSA 99 % was higher for CeO2 A and B. However, 
the different adsorption pattern for CeO2 C strongly points to different 
adsorption mechanisms compared to CeO2 A and B. 
 
 
 
Figure 3.3. Protein adsorption from different BSA derivatives and FCS with a 
particle-protein relation of 10:1 (mean ± sd, statistics: Kruskal-Wallis One-
way Analysis of Variance on Ranks, followed by pairwise comparison proce-
dure with Student-Newman-Keul-method, p<0.05). 
 
 
State of agglomeration with analytical ultracentrifugation (AUC). The 
interaction between colloids, and hence their tendency to agglomerate is 
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dictated by their surface properties – including the spontaneous change 
of surface properties due to protein adsorption. We characterized the 
state of agglomeration in FCS by AUC with interference detection. Since 
the signal height is directly linear with the concentration in the meas-
urement interval, the ultrafine fraction (below 100 nm diameter) can be 
quantified. In Figure 3.4, the resulting particle size distributions are 
shown with logarithmic axes. For stabilized CeO2 A and CeO2 B in the 
presence of serum, significant ultrafine fractions were found, whereas 
CeO2 C agglomerated stronger with two orders of magnitude less particles 
dispersed to 100 nm diameter or below. The two-peaked signal below 
10 nm diameter is attributed to the serum proteins. The peaks can be 
converted from diameters to molar masses, giving 65 kDa and 120 kDa, 
in excellent agreement with BSA monomer and dimer. Again, the signal of 
the proteins is integrated and divided by the known protein refractive in-
dex increment dn/dc = 0.18 cm³/g to provide an independent measure-
ment of the actual concentration of the protein fraction that is not ad-
sorbed on particles. 
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Figure 3.4. a) Size-distribution of the CeO2 particles after dispersion in FCS-
solution by AUC (particle-protein ratio of 1:1). The signal at 3-7 nm corre-
sponds to the sizes of BSA monomer and dimer, respectively. b) table re-
vealing the ultrafine fractions of the particles in numbers. 
 
 
AFM force-distance measurements between proteins and particles. 
Multiple preparations of adhesion force curves can be summarized to fre-
quency distribution patterns. Measuring adhesion with an unmodified 
AFM tip clearly reveals similar hydrophilic properties in a normal adhe-
sion force distribution for CeO2 A and CeO2 B (see Figure 3.5). CeO2 C 
showed multiple unspecific interactions with the unmodified hydrophobic 
Si3N4-tip. The calculated main peak for measurements with unmodified 
tip was 2.2. nN for CeO2 A (n=227), 3.3 nN for CeO2 B (n=240) and 3.9 nN 
for CeO2 C (n=283). The same experiments with covalent attached BSA at 
the apix of the tip caused lower interactions for CeO2 C (peak at 2.6 nN of 
258 measurements) and an increase up to 2.3 nN for CeO2 A (n=229) and 
3.4 nN for CeO2 B (n=266). The broader distribution of the measured ad-
hesion forces for CeO2 C with an unmodified tip changed to a narrow dis-
tribution similar to the other two CeO2 samples. 
The results of adhesion measurements of each CeO2 formulation are 
summarized in Table 3.3. There are only little differences in the calculat-
ed indentation depths for CeO2 A and CeO2 B particles with unmodified 
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AFM tips. They range from 3.4 nm for CeO2 A to 3.5 nm for CeO2 B. Low-
er values were obtained for the BSA modified tips, 3.0 nm for CeO2 A, 3.3 
nm for CeO2 B. In contrast the indention depth of the CeO2 C increases 
from 1.5 nm to 2.8 nm. 
The work of adhesion and surface free energy for the formulations using 
unmodified tips show an increasing order of the different particles. With 
unmodified tips CeO2 C has the highest Wadh and CeO2 A the lowest Wadh. 
BSA modification changed the Wadh for CeO2 A and CeO2 B, in contrast 
there is a major decrease for CeO2 C particles. 
 
 
Table 3.3. Atomic force measurements: indentation, force of adhesion, work 
of adhesion and surface free energy of all CeO2 formulations with unmodi-
fied and BSA modified tips 
formulation 
 
Force of adhe-
sion 
 (Fadh)  
[nN] 
Indentation 
[nm] 
Work of ad-
hesion (Wadh) 
[mJ*m-2] 
Surface free 
energy  
(2)  
[mJ*m-2] 
CeO2 A 
CeO2 A BSA modified 
tip 
2.166 
2.266 
3.4 
3.0 
103 
108 
64 
70 
CeO2 B 
CeO2 B BSA modified 
tip 
3.262 
3.435 
3.5 
3.3 
156 
164 
144 
160 
CeO2 C 
CeO2 C BSA modified 
tip 
3.873 
2.551 
1.5 
2.8 
184 
121 
204 
88 
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Figure 3.5. Frequency distribution of the adhesion values in the AFM force-
distance curves: CeO2 A, CeO2 B and CeO2 C particles. 
 
 
Different particle characteristics are known to determine protein (e.g. 
BSA) adsorption onto nanoparticles, and in particular hydrophobic in-
teractions tend to be the dominating feature [76-78]. Magnetic nanopar-
ticles covered with thermo sensitive PNIPAM (Poly(N-isopropylacrylamide)) 
are hydrophobic above temperatures of 32°C. Shamim et al. could show 
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that BSA-adsorption was much higher at temperatures above 32 °C. Na-
ked magnetic nanoparticles showed no increase in protein-adsorption 
with increasing temperature, i.e. protein adsorption is increasing with 
higher hydrophobicity [79]. Also, electrostatic interactions can play an 
important role [80, 81]. The amount of BSA adsorbed to magnetic nano-
particles covered with PNIPAM or chitosan increased with decreasing pH, 
whereas the maximum adsorption was near the isoelectric point of BSA 
(pI = 4.7) [79, 82]. There is strong evidence that the size of the particle 
may be another factor influencing protein adsorption. Nanoparticles of 
different sizes, but the same level of hydrophobicity show different de-
grees of Human Serum Albumin adsorption. Despite the fact that smaller 
nanoparticles reveal proportionally larger surface areas than larger ones, 
the adsorption surprisingly is in favor of the larger particles. Hence, it is 
speculated that the curvature of nanoparticles may suppress the protein 
adsorption at a particle size around 30 nm [33]. Clearly, not all proteins 
show the same adsorption patterns. Conditioning of different particles 
with complex protein mixtures, e.g. blood serum, leads to different ad-
sorption patterns for the protein fractions [83, 84]. Under well-defined 
conditions, protein adsorption data can be used in established mathe-
matic models involved: BSA-adsorption onto chitosan-coated magnetic 
nanoparticles could be fitted to Langmuir isotherms and hence quantified 
not only in terms of overall protein adsorption, but also in protein affinity 
[82]. Summarized, the protein adsorption onto particles depends on: hy-
drophobicity of the particle surface, pH, particle size and the protein(s) 
used, it might be fitted to Langmuir model under defined conditions. In 
this context, we interpreted the protein adsorption data generated with 
the CeO2 nanoparticles. 
Table 3.1 reveals close similarities in size, pH and ζ-potential for all three 
CeO2 formulations. Contact Angle, XRD, XPS and SIMS measurements 
revealed only minimal differences in surface energy, surface chemistry or 
crystallinity.   
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Nevertheless, the frequency distributions of the adhesion measurements 
showed differences between the formulations. The adhesion forces be-
tween Si3N4 tip and CeO2 A particles change only slightly by modifying 
the tip with BSA. Similar results with the AFM force measurements were 
obtained for CeO2 B particles. Based on the force curves it could be seen, 
that a modification of the surface increases interactions, e.g. electrostatic 
attractive forces. This increase in the attractive forces between particle 
and tip is proportional to the snap-in of the force-distance curves. As it 
would be expected from size and ζ-potential, CeO2 C should show a simi-
lar frequency distribution compared to CeO2 A and CeO2 B (Figure 3.5). 
However, in contrast CeO2 C displays a very broad frequency distribution 
without a significant peak. The reason for that may be non-specific inter-
actions. This behavior is totally changed when using a BSA modified con-
tact tip. The more hydrophilic surface of the tip results in specific inter-
actions thus leading to a narrow frequency distribution with a single 
pronounced peak.  
It is known that proteins are flexible and that albumin changes its con-
formation on a surface in order to minimize interface energy. Gao et al. 
described a conformational changing of BSA molecules from -helix to 
the more space requiring -sheets [85]. These possible changes in the 
conformation of the structure of the adsorbed proteins can explain the 
different indention values of CeO2 C: Note that all indention values (Table 
3.3) are lower than the BSA hydrodynamic diameter of 4.5 nm. The in-
dention nearly doubles to 2.8 nm for BSA-modified tip for CeO2 C com-
pared to around 1.5 nm for the indention with unmodified cantilever. It 
seems that BSA adsorbs in a stretched configuration as a flat layer on 
CeO2 A and CeO2 B, but stays extended on CeO2 C. This is conform to 
the differences in adsorption for BSA 99 %, FITC-BSA and protein from 
FCS (Figure 3.3) and points to a lower affinity of BSA on CeO2 C.  
Similar results were obtained with Analytical Ultracentrifugation. At a 1:1 
ratio of nanoparticles and proteins, the agglomerate diameter distribu-
tions of CeO2 A and CeO2 B, except for an insignificant shift in diameter, 
were almost identical and showed a low tendency to agglomerate with 
 54 
more than 10 wt% of the particles added dispersed below 100 nm diame-
ter. This low level of agglomeration is attributed to the presence of ad-
sorbed proteins acting as protection colloids in steric stabilization. In 
contrast, the results for CeO2 C deviate from the other two formulations. 
As shown in Figure 3.4, CeO2 C forms agglomerates, which we interpret 
to be a result of the absence of adsorbed proteins.  
All three formulations show different values in the protein adsorption de-
rived from the BCA assay data (Figures 3.2 and 3.3, Table 3.2). As ex-
pected from force measurements and AUC data, CeO2 A adsorbed more 
protein from pure BSA solution than CeO2 B and CeO2 C. The character-
istics of the sigmoidal fits of the protein absorption at different particle-
protein ratios are very similar for CeO2 A and CeO2 B.  
Looking at the BCA data only, it seems that CeO2 C might reveal the 
weakest affinity to BSA and FCS proteins in general. However, as provid-
ed by AUC measurements, CeO2 C (Figure 3.4) shows a high tendency to 
agglomerate. This intense state of agglomeration could have lead to a 
drastically decreased surface and hence to a lower overall protein adsorp-
tion. Presumably, the interaction between CeO2 C particles was higher 
than that between protein and particle, which is supported by the large 
particle size distribution in FCS.  
Our data could not be fitted to Langmuir isotherms, but had sigmoid pat-
terns. We believe this is due to the correlation between the level of ag-
glomeration and the protein concentration: The particulate surface that 
is available for adsorption is not independent of the protein concentra-
tion, as proteins can improve dispersion of the particles, which leads to 
smaller particle sizes (deagglomeration) and hence to a larger surface 
available for protein adsorption (see chapter 2, Figure 2.6). In well de-
fined colloidal systems, such as stable polymer particle dispersions with 
uniform particle sizes, this problem is not occurring. Also, here the ad-
sorption patterns are derived from a mixed influence of electrostatic and 
hydrophobic interactions (and maybe from different curvatures due to 
irregular particle shapes).  
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Protein adsorption does not necessarily occur directly to the particle, 
but can also be mediated by other substances. Here, the adsorption of 
the 96 % pure BSA seemed not to be mediated by impurities of the pur-
chased protein but was a direct particle-protein interaction, as there was 
no significant difference in adsorption compared to highly pure BSA (Fig-
ure 3.3).  
AUC quantified the adsorbed amount of specifically BSA in the FCS solu-
tion, whereas BCA-assay quantified the overall protein adsorption. Com-
parison of adsorption from FCS-solution by AUC and BCA-assay revealed 
a very good correlation for CeO2 A and B, leading to the assumption that 
BSA must be dominating the corona. Hence, CeO2 A and B seem to ad-
sorb BSA from the FCS solution very specifically, in excellent accord with 
the small indention depth in AFM, and hence extended configuration on 
the inorganic surface. Since differences for CeO2 C between BSA-specific 
detection (AUC) and unspecific detection (BCA) persist, one can speculate 
about the formation of a secondary or soft corona at lower parti-
cle/protein ratios, which would indeed shift the BSA adsorption isotherm 
in the observed direction, supported also by the larger indention depth. 
At present, this last detail remains open.  
  
3.5 Conclusion 
In this chapter, protein interactions of BSA with and adsorption of BSA 
or FCS as a complex protein mixture to nanoparticles was investigated. 
Clearly, generation as well as interpretation of protein adsorption or in-
teraction data with metal oxide nanoparticles was difficult and methods 
from different physical, chemical and mathematical principles were nec-
essary to succeed. It was demonstrated that nanoparticles from nominal-
ly the same inorganic material do not necessarily reveal the same adsorp-
tion patterns to proteins. As the state of agglomeration is depending on 
the protein concentration, the available particle surface and the protein 
adsorption influence each other, impeding the use of standard adsorption 
models as Langmuir. Also, the higher particle-particle interactions of 
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CeO2 C may falsify the protein affinity due to a strong agglomeration ten-
dency and decreased surface. The BSA adsorption detected in this work 
was a direct particle-protein interaction and not mediated by impurities. 
Finally, it was pointed out that CeO2 A and B adsorbed BSA from a FCS-
solution very specifically, and that BSA does change its conformation on 
the nanoparticle surface. 
Particle-protein interaction could be proven for three different CeO2 na-
noparticles with similar physico-chemical characteristics. Based on our 
intention to determine structure-effect relations we proved that it is not 
sufficient to characterize intrinsic properties only, where only minute var-
iations were detected. The variations were considerable in the next step of 
the biodistribution, namely in the adsorption of serum proteins albumin, 
mimicking the interaction after uptake into the blood system. The same 
must be expected in the lung for the interaction with surfactant proteins 
after inhalative exposure. In order to derive structure-effect relations, in 
situ or as-tested characterization, not as-produced is required, with im-
plications for the discussion of 'Sameness' in the REACH Implementation 
Project on Nanomaterials.
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4.1 Abstract 
The pulmonary surfactant, a major component of the Alveolar Lining Flu-
id (ALF) covering the respiratory epithelium of the deep lung is the first 
biological barrier encountered by nanoparticles after inhalation. We here 
report for the first time significant differences for metal oxide nanoparti-
cles to the binding of Surfactant protein A, the predominant protein com-
ponent of pulmonary surfactant. SP-A is a physiologically most relevant 
protein and provides important biological signals. Also, it is involved in 
the lung's immune defence, controlling e.g. particle binding, uptake or 
transcytosis by epithelial cells and macrophages. In our study, we could 
prove different particle-protein interaction for eight different nanoparti-
cles, whereas particles of the same bulk material revealed different ad-
sorption patterns. In contrast to other proteins as Bovine Serum Albumin 
(BSA), SP-A does not seem to significantly deagglomerate large agglomer-
ates of particles, indicating different adsorption mechanisms as in the 
well-investigated model protein BSA. These findings may have important 
consequences for biological fate and toxicological effects of inhaled na-
nomaterials. 
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4.2 Introduction 
As pointed out previously, the interactions of proteins and nanoparticles 
are of the utmost importance when they come in contact with biological 
systems. It is known that small particles are taken up in higher amounts 
than larger ones, so the level of particle uptake into cells could be altered 
due to protein coating of particles, which was proven to lead to deag-
glomeration (see chapter 2, Figure 2.6) and hence to smaller particle siz-
es. Also, it could be demonstrated that model protein BSA is adsorbing 
onto CeO2 nanoparticles (see chapter 3, Figures 3.2 and 3.3, Table 3.2). 
There is also evidence that particles coated with proteins adsorbed onto 
endothelial cells in higher amounts as uncoated ones [84]. Hence, the 
phenomenon of protein adsorption onto nanoparticles entering biological 
systems could lead to significant toxicological consequences and must be 
investigated thoroughly. 
The Dawson group has pioneered structure-property-relationships in 
protein coronas during the last few years using plasma proteins [59, 60, 
86, 87]. However, there is general consensus in nanotoxicology that inha-
lation represents the most relevant route of exposure [61]. As stated pre-
viously, the first biological barrier that inhaled particles will encounter is 
the pulmonary surfactant (a component of the alveolar lining fluid (ALF)), 
an ultra thin liquid layer covering the respiratory epithelium towards the 
air side. The pulmonary surfactant consists of approximately 90% lipids 
(mainly phospholipids) and 10% proteins (so called surfactant proteins, 
Sp-X) by weight [20]. Concerning the interaction between the ALF and 
inhaled particles, we assume that especially the four so called lung sur-
factant proteins play a key role. Surfactant protein B and C are very lipo-
philic and improve the surface activity of surfactant phospholipids [88]. 
The more hydrophilic Surfactant proteins A and D (Sp-A, Sp-D) belong to 
the collectins recognizing, binding and facilitating the clearance of infec-
tious particles from the lung [89]. As Sp-A is the most prominent of the 
four surfactant proteins and because of its major role in lung immune 
defence, a possible particle interaction with this protein is highly im-
portant to understand and to predict further biological responses. The 
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adsorption of ALF components has already been addressed in several 
studies for diesel soot, quartz and kaolin particles [90], as well as for gold 
[91], TiO2 [92] and polystyrene particles [93], but they predominantly 
concentrated on the lipid fraction of ALF. Therefore, the interaction of 
metal oxide nanoparticles with lung surfactant proteins present in por-
cine Broncheo-Alveolar Lavage Fluid (pBALF) was studied.  
To investigate nanoparticles-protein interactions microcalorimetry and 
surface plasmon resonance technique were introduced by Cedervall et al. 
using co-polymer particles as model [33]. However, these techniques were 
not readily transferable to “real” nanomaterials, such as e.g. metal ox-
ides, mainly due to rapid sedimentation. Hence, the colorimetric BCA-
assay, gel-electrophoresis and immunoblotting was used to quantify and 
identify the interacting proteins. Also, the agglomeration behaviour of 
those particles in pBALF was investigated and compared to that of com-
monly used FCS. 
 
4.3 Materials & Methods 
Materials. The Bicinchinoninic Acid Kit for Protein Determination (BCA 
assay), TRIS-HCl, glycerine, β-Mercaptoethanol, TWEEN 80, NaCl and 
MgCl2 were purchased from Sigma-Aldrich Chemie GmbH, Munich, Ger-
many. Acrylamid solution Rotiphorese Gel 40 (29:1), Temed, glycin and 
Ammoniumperoxodisulfate (APS) were from Carl Roth GmbH & Co., 
Karlsruhe, Germany. The nitrocellulose membranes (Whatman Protran 
BA 85 Nitrocellulose) were bought from Biometra, Goettingen, Germany. 
The protein marker was from Fermentas GmbH, St. Leon-Rot, Germany. 
The primary and secondary antibodies (Rabbit Anti-Surfactant Protein A 
and Alkaline Phosphatase conjugated goat anti-rabbit IgG) were pur-
chased from Millipore GmbH, Schwalbach, Germany. The NTB/BCIP so-
lution was bought from Roche Diagnostics GmbH, Mannheim, Germany. 
From SERVA Electrophoresis GmbH, Heidelberg, Germany, we used So-
dium-dodecylsulfate (SDS). Methanol was HPLC grade from Fisher Scien-
tific GmbH, Schwerte, Germany. Bromphenolblau was purchased from 
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Pharmacia Biotech AG, Duebendorf, Germany. The low-fat milk (1.5 %) 
was bought from a local dairy. 
Determination of protein adsorption onto metal oxide nanoparticles 
via BCA-assay. 148 mg of nanoparticles were dispersed with 2 ml of a 
1:10 diluted pBALF solution (leading to a protein concentration of 7.4 
mg/ml), leading to particle-protein ratio of 10:1. The resulting disper-
sions were stirred at room temperature for 1 h at 300 rpm, transferred 
into Eppendorf tubes and centrifuged at 23000 g for 45 min and 10 °C in 
a Hettich Universal 30 RF with rotor E1175 (Hettich Lab Technology, 
Tuttlingen, Germany). Afterwards, the supernatants were used for BCA-
assay as described in the manual. The resulting protein concentrations 
in the supernatants were subtracted from the original concentration and 
related to the negative control (centrifuged protein solution without parti-
cles). 
Preparation of porcine Broncheoalveolar Lavage Fluid (pBALF). 
pBALF preparation was modified after [94]. In short, three porcine lungs, 
derived from a local butcher and removed in toto, were filled with cold 
(4 °C) purified water (Millipore GmbH, Schwalbach, Germany) and gently 
massaged for about 5 min. Then, the fluid was removed and collected; 
the fluid of all lungs was pooled and centrifuged at 1400 rpm for 4 min to 
remove cellular residues. The thus obtained volume of about 2 l of pBALF 
was freeze-dried in a Christ Alpha 2-4 LSC (Martin Christ Gefriertrock-
nungsanalgen GmbH, Osterode am Harz, Germany) lyophilisation device 
and rediluted in 200 ml of purified water in order to concentrate the pro-
teins. The content of soluble compounds was determined gravimetrically 
to be 74,03 mg/ml. The content of Sp-A was proven by Westernblotting 
and Immunostaining as described later, in comparison to literature [95, 
96] and a Sp-A reference. The pBALF was aliquoted and stored at -80 °C 
until use. The time frame between picking up the lungs and preparation 
of the pBALF was about 45 min. During the whole transportation pro-
cess, the lungs were cooled on ice to preserve the tissue. After they ar-
rived in the laboratory, we started pBALF preparation immediately.  
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SDS-PAGE, Western Blotting and Immunostaining. The contents and 
preparation of all buffers and solutions are summarized in Table 4.1.  
After incubation with the nanoparticles in a particle-protein relation of 
10:1 and centrifugation, the supernatants were removed, the pellets 
rinsed 3 times with purified water and resuspended with 0.5 ml of puri-
fied water. 0.1 ml of the supernatants and pellet dispersions respectively 
were mixed with 0.1 ml of 2x sample buffer and denatured for 5 min at 
95 °C to detach the proteins from the particles. Then, 20 µl of each sam-
ple was pipetted into the pockets of a 12 % Polyacrylamide gel (4.5 ml of 
purified water, 2.5 ml of separation gel buffer, 3 ml of Acrylamid solution 
(Rotiphorese Gel 40 (29:1)),  0.05 ml of Ammoniumperoxodisulfate (APS) 
0.005 ml of Temed), covered with a 4 % stacking gel (2.5 ml of purified 
water, 0.95 ml of stacking gel buffer, 0.4 ml of Acrylamid solution, 
0.0225 ml of APS, 0.0075 ml of Temed) and run, soaked in running buff-
er, for 110 min at 100 V in a MiniProtean II (Bio-Rad Laboratories GmbH, 
Munich, Germany).  
The stacking gels were removed and the separation gels covered with ni-
trocellulose membranes, sandwiched in filter paper and soaked in blot-
ting buffer. After removing air bubbles from the layer interspaces, the 
blotting sandwiches were transferred into a Mini Trans-blot Cell (Bio-Rad 
Laboratories GmbH, Munich, Germany) and tank-blotted in blotting buff-
er at 300 mA for 90 min. As the protein marker was prestained, there 
was no need to check the protein transfer by Ponceau staining.  
 The membranes were blocked for 2 h in blocking buffer, then they were 
incubated with Rabbit Anti-Surfactant Protein A at a dilution of 1:2500 
in blocking buffer (Anti-Surfactant Protein A) for 2 h under gentle luffing. 
The blots were washed 3 times with TBS buffer for 10 min prior to incu-
bation with Alkaline Phosphatase conjugated goat anti-rabbit IgG (Goat 
anti-Rabbit IgG, Alkaline Phosphatase Conjugated), diluted 1:5000 in 
blocking buffer. After washing 3 times for 10 min with TBS buffer, the 
blots were developed in 10 ml of NBT-BCIP dying solution for several 
minutes. Finally, the blots were scanned and saved as .tiff files.  
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Table 4.1: Buffers and solutions needed for SDS-PAGE, Westernblotting and 
Immunostaining. 
 components concentration 
stacking gel buffer 
Tris-HCl 
SDS 
adjust to pH 6.8 
0.5 M 
0.4 % (w/v) 
separation gel buffer 
Tris-HCl  
SDS  
adjust to pH 8.8 
1.5 M 
0.4 % (w/v) 
2x sample buffer 
Tris-HCl  
SDS 
Glycerin  
β-Mercaptoethanol 
Bromphenolblau 
adjust to pH 6.8 
0.12 M 
8 % (w/v) 
20 % (w/v) 
10 % (v/v)  
0.1 % (w/v) 
running buffer 
Tris 
Glycin 
SDS 
0.025 M 
0.192 M 
0.1 % (w/v) 
blotting buffer 
 
Tris-HCl 
Glycin 
Methanol 
pH 8.3 
0.025 M 
0.192 M 
20 % (v/v) 
TBS buffer 
Tris-HCl 
NaCl  
pH 7.5 
0.02 M 
0.15 M 
blocking solution 
low-fat milk (1.5 %) 
TWEEN 80 
in TBS buffer 
10 % (v/v) 
0.1 % (v/v) 
buffer for  NTB/BCIP 
dying solution 
Tris-HCl 
NaCl 
MgCl2 
pH 9.5 
0.1 M  
0.1 M 
0.05 M 
NTB/BCIP dying solution 
NTB/BCIP stock solution  
in buffer for NTB/BCIP dying solu-
tion 
0.2 % 
 
 
Agglomeration control by Analytical Ultracentrifugation (AUC). The 
particle size distribution was determined by analytical ultracentrifugation 
(AUC) of ~500 μL of the test dispersion with a mass ratio of nanomaterial 
: BALF proteins = 2:1. This ratio corresponds to around 10 mg/cm2 pro-
tein mass concentration / nanomaterial specific surface in the solution 
and it was chosen because this situation is close to a particulate contam-
ination in the lung: Only a small part of the available protein mass has 
adsorbed. 
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Simultaneous detection by synchronized interference optics (Beckmann, 
model XLI) quantified the amount and the diameter of each fraction inde-
pendently from 1 nm up to several microns in diameter [36, 37, 61]. We 
can thus successively quantify in a single measurement both the protein 
content, the protein molar mass, the nanomaterial content, and the na-
nomaterial state of agglomeration, presented as double-logarithmic plot 
in Figure 4.3. When the retrieved concentration of proteins is less than 
100wt% at the expected molar mass, we assume that the remaining pro-
teins have adsorbed to a particulate surface. When the retrieved concen-
tration of nanomaterial is less than 100wt% in the measurement interval, 
we assume that the remainder has agglomerated. The evaluation of the 
AUC raw data incorporated the fractal morphology of nanoparticle ag-
glomerates and applied the fractional dimension of 2.1 together with the 
sedimentation relation as specified in Eq. (6) of the reference [38]. This 
value of the fractional dimension has been shown to be universal for all 
reaction-limited colloid agglomerates [38, 39]. The tabulated material's 
constant of refractive index allows the interference optics to linearly di-
rect quantify the fraction that is dispersed to diameters below 100 nm in 
the actual test preparation, with the full size distributions shown in the 
integrated table in Figure 4.3. The value for the nanodispersed fraction is 
regarded as an upper limit, judging from the comparison of size determi-
nation methods with different physical measurement principles (see 
chapter 2, Figure 2.6). 
Nanoparticles. To be able to interpret the protein adsorption patterns 
and to show the high variability of the particles we were dealing with, we 
tried to characterize the nanoparticles we worked with (see Table 4.2 and 
Figure 4.1).  
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Table 4.2: Physico-chemical properties of the nanoparticles tested (the data 
are adopted from [35]) 
sample 
chemical 
composition, 
crystallinity 
mean prima-
ry particle 
size, mor-
phology 
surface 
area 
[m2/g] 
surface 
chemis-
try 
[At%] 
organic 
modi-
fication 
pH# 
BaSO4 
56,5 % Ba 
38.6 % SO4 
orthorhombic 
38 nm 
irregular but 
globular 
41,4 
Ba 13 
S 11 
O 52 
C 17 
yes 8.6 
AlOOH 
82.7 % 
AlOOH; 
impurities: C, 
Na, Fe, Si, Li, 
B 
40 nm, 
irregular but 
spherical 
 
47 
O 62 
Al 32 
C 7 
 
none 4.3 
TiO2 A 
O 58 % 
Ti 41 % 
Cl > 1 % 
anatase 95 %, 
rutile 5 % 
17 nm 
irregular but 
spherical 
117 
O 53 
Ti 21 
C 25 
Cl 1 
yes 5.4 
TiO2 B 
>99.5 % TiO2 
rutile and 
anatase, 
tetragonal 
27 nm irregu-
lar but globu-
lar 
52 
O 58 
Ti 26 
C 14 
N 0.5 
Cl 1 
none 6.1 
CeO2 A 
> 99.97 % 
purity 
14 nm 
cubic, aggre-
gated 
63 
O 57 
Ce 25 
C 18 
none 5.9 
CeO2 B 
> 99.97 % 
purity 
20 nm, 
aggregated 
44 
O 56 
Ce 22 
C 22 
none 6.2 
CeO2 C 
>99 % CeO2 
Cerianite, 
cubic 
70 nm irregu-
lar but globu-
lar 
33 
O 53 
Ce 26 
C 20 
Cl 0.6 
none 5.9 
Carbon 
black 
n.d. 
16 nm, aggre-
gated 
340 n.d. none 5 
#10 mg/ml of nanoparticle in purified water 
n.d. not determined 
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Figure 4.1. TEM pictures of the different nanoparticles tested for protein ad-
sorption. The particles were dispersed in isopropanol and dried before use. 
 
 
4.4 Results & Discussion 
Direct and indirect analysis of SP-A adsorption onto metal oxide na-
noparticles. The protein adsorption on nanoparticles was determined by 
measuring the protein content in the supernatant (BCA-assay) and ex-
pressed as a percentage of the protein content in a similarly treated 
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pBALF sample without nanoparticles. Clearly, different particles show a 
different protein adsorption (see Figure 4.2a), BaSO4 and TiO2 A generally 
adsorbing much less protein than the rest of the particles tested. Also, 
different particles of the same bulk material reveal different adsorption 
patterns, as could be shown for CeO2 A and B compared to CeO2 C and 
for the two TiO2 particles. 
The pulmonary surfactant is a complex mixture of lipids, phospholipids 
and proteins important for normal respiratory function [97]. Among the 
four lung surfactant proteins known, i.e. Sp-A, Sp-B, Sp-C and Sp-D, Sp-
A is by far the most abundant (approximately 90 %) [96, 98, 99] and spe-
cific antibodies are commercially available, hence, we decided to focus 
our further experiments on Sp-A. Sp-A consists of eight trimers, each of 
those trimers including a long triple helical collagenous stem, a flexible 
hinge, a helical bundle connector and a globular head [100-102]. This 
globular structure contains Carbohydrate Recognition Domains (CRDs), 
and as Sp-A is a member of the collectin protein family, it recognizes and 
binds carbohydrates in a Ca2+-dependent process as a part of the im-
mune defence system [97, 103]. Also, Sp-A is able to bind multiple lig-
ands as sugars, Ca2+ and phospholipids in a cooperative manner [100], 
allowing Sp-A to bind to the surface of multiple pathogens like bacteria, 
viruses and funghi [89], but also associates with the lipid fraction of 
pulmonary surfactant via those globular structures [104, 105]. 
To measure the binding of SP-A onto the metal oxide nanoparticles, sam-
ples of both the supernatant and the pellet of the previously described 
adsorption experiment were each analyzed by SDS-PAGE under reducing 
conditions, followed by Western blot and immunostaining (Figure 4.2b).  
TiO2 A and BaSO4 showed relatively low overall protein adsorption (30 % 
and 5 %, resp.), but nevertheless high Sp-A interaction as suggested by a 
strong SP-A signal in the pellet and a weak (TiO2 A) or no (BaSO4) signal 
in the supernatant. Obviously, those particles are adsorbing Sp-A very 
specifically. For the model protein BSA protein adsorption has been re-
ported to be pH dependent, the maximum being near its isoelectric point 
[79, 82]. This, however, might not be transferable to the adsorption of Sp-
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A to BaSO4, as the pH of the BaSO4 dispersion of 8.6 differs from the pI of 
Sp-A of 4.4-5.6. Interestingly, according to the manufacturer´s specifica-
tions, both TiO2 A and BaSO4 bear some organic modifications (Table 
4.2). As pBALF is not Ca2+-free, an ion-mediated adsorption to the organ-
ic groups of the two particles via the CRD domain of Sp-A may be possi-
ble, similarly as has been suspected by Salvador-Morales and Co-workers 
for accidental organic modifications of carbonanotubes [106]. 
AlOOH and CeO2 C show an intermediate overall binding of pBALF pro-
teins (Figure 4.2a). In contrast, binding of Sp-A to CeO2 C was only weak, 
as indicated by the fact that the strongest signal was found in the super-
natant and the weaker signal in the pellet. For AlOOH, Sp-A was only de-
tected in the pellet, similar as for BaSO4.  
Strongest (~ 100 %) overall protein binding in pBALF was observed with 
TiO2 B, CeO2 A and B and carbon black. For neither of those particles 
any SP-A signal could be detected in the supernatant. For TiO2 B and 
CeO2 B, similar Sp-A adsorption to the nanoparticles was observed (in-
termediate Sp-A signal in the pellet). Only a very weak Sp-A signal was 
found for the CeO2 A pellet, whereas carbon black revealed no Sp-A sig-
nal at all. The reason might be an extremely strong binding of the Sp-A to 
the surface of those types of nanoparticles, even resisting the conditions 
of the desorption protocol used in this study. As we stated previously, the 
globular domains of SP-A do not only bind to carbohydrates, but also to 
phospholipids. Although this interaction is considered superficial, it has 
hydrophobic and polar contributions [100]. As carbon black is very hy-
drophobic, a hydrophobic interaction between carbon black and the 
globular side of Sp-A might be speculated, boosted by the largest BET 
surface of all particles tested (340 m2/g). This also adds to the high af-
finity of overall protein binding, causing failure of the desorption protocol 
and hence empty lanes on the gels for both supernatant and pellet. 
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Figure 4.2. Adsorption of proteins from pBALF at a nanoparticle/protein ra-
tio of 10:1. a) Total protein adsorption (BCA assay): The particles show 
striking differences, even when derived from the same bulk material. All 
values were related to the pBALF-supernatant after nanoparticle separation 
by centrifugation (mean + standard deviation; n=3). b) Immunoblot of Sp-A 
from supernatant and pelleted nanoparticles after conditioning in pBALF 
(Sp-A monomer: 36 kDa). As control, pBALF 1:10 diluted was used.  
 
 
It is known that protein adsorption is depending on the hydrophobicity of 
the particle surface [76-78]. As stated previously, 90 wt% of ALF are 
(phospho)lipids and we cannot exclude the possibility of at least a partial-
ly washout of this lipid fraction into our pBALF. Hence, an indirect ad-
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sorption mechanism, mediated or influenced by those lipids, is most like-
ly. 
Comparing the binding of pBALF proteins and in particular SP-A to the 
different nanomaterials in this study, no striking differences could be ob-
served, even for nanoparticles made of the same material (e.g. CeO2 A 
versus B or C; TiO2 A versus B). There was no obvious correlation to 
physico-chemical data such as the mean primary particle size, surface 
area, etc. (Table 4.2), which would allow a prediction of protein binding 
from such data. 
Investigation of deagglomeration capacity of pBALF. Complementary 
to protein binding, also the agglomeration behaviour of the same parti-
cles in pBALF was studied, as this is the second property that decides 
about a nanoparticle‟s trafficking in the body. Analytical Ultracentrifuga-
tion (AUC) with interference detection provides a signal that is directly 
linear with the concentration in the measurement interval [61]. The ul-
trafine fraction (below 100 nm diameter) can be quantified. In Figure 4.3, 
the resulting particle size distributions are shown with logarithmic axes. 
Only TiO2 A and BaSO4 are dispersible by stirring in water with 40 wt% 
and 0.5 wt% ultrafine fraction, respectively. For the more hydrophobic 
materials (carbon black, unfunctionalized metal oxides), less than 0.01 
wt% ultrafine fraction is found in water, but media with serum or Sp-X 
enhance wetting and lower the degree of agglomeration. The detailed size 
distributions (Figure 4.3) indicate that agglomeration tendency in pBALF 
is significantly stronger than in Fetal Calf Serum (FCS; Figure 4.3, in-
serted table), which is widely used in cell culture media. Several studies 
have hinted at the dispersing power of albumin and other interface-active 
serum components on CNTs [29, 107, 108], metal carbide nanoparticles 
[109, 110] and metal oxide nanoparticles [109-112]. For mouse BALF, the 
degree of agglomeration of metal oxide nanoparticles was reported to be 
comparable with a buffer containing BSA and dipalmitoyl phosphatidyl 
choline [113] and in a BAL-mimicking dispersion medium [114], but only 
after 10 min. ultrasonication. Obviously, the anticipated interface activity 
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of Sp-X is in general not sufficiently strong to overcome the agglomera-
tion tendency due to other components in complete pBALF. This result is 
in good agreement with histological studies of lung slices after inhalation 
exposure of rodents, where the particulate material that was deposited on 
the lung surface is found in the form of agglomerates [114].  
The differences in protein adsorption of FCS compared to pBALF can also 
be seen in Figure 4.4: For six of the eight particles tested, there was a 
significant difference in protein adsorption for FCS at a particle-protein 
ratio of 10:1.  
 
 
 
Figure 4.3. Full particle size distribution of nanoparticles in diluted pBALF 
(from interference-AUC). The table shows the initial weight ratio and the 
protein and particle concentrations within the shown size interval as well as 
the resultant ultra fine fraction of the particle suspension.  
 
 
After inhalation and deposition in the deep lung, i.e. ALF, particles with a 
diameter of 1-6 µm are wetted and sink into the aqueous phase [23], 
whereas this mechanism is independent of shape, surface topography 
and surface free energy [115-118]. This process becomes even more effi-
cient with decreasing particle size and this is expected to occur with na-
noparticles, too [119]. As SP-A is integrated into the lipid structure of 
ALF, the tested nanoparticles most likely come in contact with SP-A in 
vivo. 
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Figure 4.4. Comparison of pBALF and FCS adsorption onto metal oxide nano-
particles at a particle-protein relation of 10:1, determined with BCA-assay 
(statistics: Kruskal-Wallis One-way Analysis of Variance on Ranks, followed 
by pairwise comparison procedure with Student-Newman-Keul-method, 
p<0.05). 
 
 
The results clearly show that there are specific differences in the binding 
and interaction of metal oxide nanoparticles with Sp-A. A major biological 
role of Sp-A is to bind to inhaled particulate matter (e.g. microorganisms, 
dust, etc) to enhance their phagocytic clearance by macrophages [106, 
120, 121]. In this way, SP-A plays an important role in limiting pulmo-
nary infection, lung allergy and inflammation [95]. On the one hand, the 
binding pattern of Sp-A and other lung surfactant proteins may be deci-
sive whether inhaled particles will be phagocytosed by macrophages and 
hence cleared from the deep lung to the airways. Although Geiser and 
colleagues found that the lung surface macrophages do not efficiently 
phagocytose these ultrafines but take them up in a rather sporadic and 
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unspecific way [122], most of our particles were highly agglomerated and 
thus still large enough for this clearance pathway. On the other hand, 
uptake and hence translocation of particles might be facilitated, as Type 
II cells, which cover the majority of the alveolar region, have Sp-A recep-
tors that cause Phospholipid uptake [123]. Nanoparticles could be taken 
up "accidentally" via this surfactant trafficking. This theory is supported 
by data from in vivo experiments that also indicate nanoparticle uptake 
into epithelia of the respiratory tract via transcytosis and translocation 
into the lymphatic system or the blood stream [25]. 
 In another way, the interaction of Sp-A with inhaled metal oxide nano-
particles could be important, as a relative Sp-A deficiency could occur 
due to its accumulation onto particles. Sp-A knockout mice are less effec-
tive in clearing lung pathogens and therefore these mice are more sus-
ceptible to lung infection. Sp-A deficient animals also present decreased 
phagocytosis and oxidant metabolism in response to instilled Group B 
streptococci [124]. There are even a few publications indicating disease 
correlation with lowered levels of Sp-A in humans. These include associa-
tion of lowered SP-A levels with asthma and allergen-induced bronchial 
inflammation [97, 103]. Obviously, there are strong reasons to assume 
that the binding to Sp-A, and probably other lung surfactant proteins as 
well, can alter the toxicological properties of particulate matter, such as 
metal oxide nanoparticles, reaching the deep lung after inhalation drasti-
cally. 
Strikingly, only the two particles that were organically functionalized with 
synthetic polymers (BaSO4 powder and TiO2 A) did not almost completely 
agglomerate after pBALF exposure. These are the same particles that dif-
ferentiated by low overall protein adsorption, but strong Sp-A interaction 
(see Figure 4.2). This points again to the decisive role of the surface 
chemistry in nanotoxicology, and opens routes to control the fate of na-
nomaterials in the lung.  
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4.5 Conclusion 
In this study, for the first time, differences in the interaction of industri-
ally relevant metal oxide nanoparticles with physiologically relevant lung 
surfactant protein A were demonstrated. Attempts to correlate the ad-
sorption patterns of Sp-A to those of commonly used model proteins 
failed, underscoring the need to apply sufficiently specific and sensitive 
analytical methods. In the future, further adsorption experiments with all 
four surfactant proteins must be performed to find out more about the 
structure activity relations between particles and their binding of lung 
surfactant proteins. Also, the effects of lung surfactant protein adsorp-
tion onto particles and their biological properties, in particular lung 
clearance by macrophages and translocation across the alveolar epitheli-
um, must be investigated. 
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5 Transport of metal oxide nanoparticles across an in 
vitro air-blood barrier model: adaptations and results 
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5.1 Abstract 
As inhalation is the major exposure route for nanoparticles, the question 
if inhaled particles can overcome the alveolar barrier and hence enter the 
body is of great interest. Here, we adapted the for soluble substances well 
established Calu-3 in vitro air-blood barrier model to the use of nanopar-
ticle transport testing. As the usually used filter supports hindered parti-
cle transport due to their small pore size, supports with a pore size of 
3 µm had to be used. On those filters, barrier and transport characteris-
tics of the cells were tested and culture conditions changed to gain opti-
mal conditions. Functionality was confirmed with transport experiments 
with polystyrene model particles prior to testing of industrially relevant 
engineered metal oxide particles. Except for CeO2 nanoparticles, no 
transport across the epithelial barrier model could be detected. For ZrO2 
nanoparticles, a compromised barrier function could be detected.  
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5.2 Introduction 
As mentioned before, inhalation of nanoparticles into the lung is probably 
the most important route for nanoparticle exposure, especially as trans-
location of nanoparticles over the air-blood barrier into secondary target 
organs was recently proven in rats for iridium and carbon nanoparticles 
[125]. Overcoming the alveolar epithelium to access the blood stream 
might bear some risks: Instillation experiments with rats showed an in-
creased carcinogenicity for TiO2 and carbon black nanoparticles [126]. 
Also, numerous publications report cytotoxic effects or the provocation of 
oxidative stress in in vitro assays for silver [127, 128], iron oxide and 
manganese oxide [129] and silica nanoparticles [130]. Hence, the safety 
of nanoparticles is a major issue that needs attention and further investi-
gation. Some in vivo inhalation and instillation experiments have been 
performed, mostly in rats, already. But for broad testing, in vitro assays 
were simpler, less time consuming, cheaper and ethically unproblematic. 
Grown on so called Transwell® filter devices, Calu-3 cells develop a tight 
monolayer, mimicking the alveolar air-blood barrier. In contrast to other 
in vitro lung models like the cell line A549, they develop tight junctions, 
which are the prerequisite for an intact barrier function and selective 
transport procedures [131]. Transport of substances from one side to the 
other can be due to different mechanisms: on one hand, the substance 
can be actively taken up into the cell, be transported through it and then 
released on the other side again (transcellular transport). On the other 
hand, opening of the tight junctions can occur, whereas either the sub-
stance per se or the cell itself can trigger this opening (paracellular 
transport). This model is well-known and characterized for soluble sub-
stances, e.g. pharmaceutically relevant chemicals, already [132-137]. 
However, to this type of experiments the pores of the support membrane 
for the cells has normally a diameter of 0.4 µm, which is in the range of 
the nanoparticles in use. Therefore, the model had to be tested and 
adopted for the use of those metal oxide nanoparticles, i.e. the filter in-
serts have to be replaced by inserts with a larger pore size of 3 µm. As 
those filter inserts reveal different properties (see Figure 5.1), the cells 
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might not be cultivated on those inserts, or they could grow through the 
pores and clog them, negating particle transport.  
In this chapter, the necessary adaptations to the Calu-3 air-blood barrier 
model are reported, as well as characterized and compared to standard 
procedure. The functionality was proven by transport assays with poly-
styrene model particles prior of using this model for transport experi-
ments with commercially available ZrO2, AlOOH and two different TiO2 
and CeO2 nanoparticles. 
 
 
 
Figure 5.1. Comparison of Transwell® filter systems for use in transport as-
says: a) System for dissolved drugs, b) adapted system for nanoparticle 
transport. 
 
 
5.3 Materials & Methods 
Materials. Polystyrene nanoparticles were purchased from Polysciences 
Europe GmbH, Eppelheim, Germany. All ingredients for Krebs-Ringer 
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buffer (KRB; 114.2 mM NaCl, 3 mM KCl, 1.5 mM K2HPO4 x 3 H2O, 
10 mM HEPES, 4 mM D-Glucose, 1.4 mM CaCl2, 2.56 mM MgCl2) and 
PBS (137 mM NaCl, 8.1 mM Na2HPO4 x H2O, 2.7 mM KCl, 1.5 mM 
KH2PO4, pH 7.4), as well as Bovine Serum Albumin, Na-Fluorescein, Tri-
ton X and Paraformaldehyde were from Sigma-Aldrich Chemie GmbH, 
Munich, Germany. The Transwell filter systems with a pore size of 0.4 µm 
and 3 µm were bought from Corning Inc., Corning, USA. RPMI 1650 me-
dium and Fetal Calf Serum Gold (FCS Gold) were from PAA Laboratories 
GmbH, Cölbe, Germany, Na-Pyruvate solution from Cambrex GmbH, 
Taufkirchen, Germany. Xylol, alcian blue, Kernechtrot and Roti-Histokitt 
were purchased from Carl Roth GmbH + Co. KG, Karlsruhe, Germany. 
Propranolol-Hydrochloride was from Synopharm, Barsbuettel, Germany. 
Leica Histowax paraffin was bought from Leica Microsystems Inc, Ban-
nockburn, USA. 
Permeation of polystyrene nanoparticles through filters of different 
pore sizes without cells. Polystyrene nanoparticles with a diameter of 
0.05 µm, 0.1 µm or 0.2 µm, carboxylated or plain, were dispersed in KRB 
+ 1 % Bovine Serum Albumin in a concentration of 224 µg/ml (corre-
sponding to a concentration of 100 µg/cm2). The apical compartments of 
the Corning Transwell systems with a pore diameter of 0.4 µm or 3 µm 
were filled with 0.5 ml of particle dispersion. The basolateral side was 
filled with KRB + 1 % BSA and incubated under shaking at 200 rpm for 
6 h at 37 °C in an incubator. After 6 h, samples from apical as well as 
from the basolateral compartments were taken and fluorescence read out 
(λex= 485/20 nm; λem= 530/30 nm, Multiwell Plate Reader from Tecan 
Group Ltd., Maennedorf, Switzerland) to quantify the amount of particles 
in each compartment. Total recovery was determined as the amount of 
nanoparticles in the apical and basolateral compartment in comparison 
to the initially applied amount and was found as 100 ± 10 %.  
Calu-3 cell culture. Calu-3 cells from American Type Culture Collection, 
Manassas, USA, were grown in RPMI 1650 medium with a supplement of 
5 ml of Na-Pyruvate and 10 % FCS Gold up to 90 % of confluence and 
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splitted once a week in a ratio of 1:5 to 1:7. The passages from 28 to 50 
were used for experiments.  
For the preparation of transport assays, 105 cells/well were seeded in 
Transwell inserts and cultured for 7-10 days prior to use. Only cell 
monolayers with TEER values of > 800 Ωcm2 were used for experiments. 
Cross sections and staining of Calu-3 cells on filters with different 
pore sizes. Cell layers grown on filters with 0.4 µm or 3 µm were cut off 
from the Transwell system including the filter membrane at day 10 or 7 
respectively and fixated in 4 % Paraformaldehyde in PBS. The filters were 
embedded into paraffin (Leica Histowax), cut in 4 µm slices and collected 
on glass slides. After prewarming them for 15 min at 37 °C, the samples 
were incubated in xylol for 5 min prior to incubation in a descending iso-
propanol series for 5 min for each alcohol concentration (100 %, 96 % 
and 70 % in deionized water). After rinsing in deionized water for 5 min, 
the samples were dyed with alcian blue (in 3 % acetic acid) for 30 min 
prior to rinsing with deionized water. Then, the samples were incubated 
with Kernechtrot and rinsed with deionized water again. After incubation 
in an ascending isopropanol series (conversely to the descending series) 
the samples were kept in xylol for 5 min and covered with Roti-Histokitt. 
TEER profile of Calu-3 cells grown on filter inserts with different 
pore sizes. The cells were cultured as described above and seeded into 
the filter inserts with a density of 0.75·105, 1·105 or 1.25·105 cells/well. 
TEER values were measured with a voltohmmeter equipped with STX-2 
chopstick electrodes (Evom from World Precision Instruments, Berlin, 
Germany) directly after seeding and then before every change of medium, 
until the TEER values clearly have passed their maximum. 
Transport assays with model substances Na-Fluorescein and Pro-
pranolol. The test substances were dissolved in KRB in a concentration 
of 30 µM and added to the apical side. Samples were taken from the ba-
solateral compartment directly after application, after 15 min, 30 min, 
45 min, 60 min, 90 min and 120 min, the volume was refilled with pre-
warmed KRB. Propranolol-Hydrochloride was quantified with High Pres-
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sure Liquid Chromatography as described previously by Becker and col-
leagues [138], Na-Fluorescein with a Tecan Multiwell reader (λex= 485/20 
nm; λem= 530/30 nm).  
Transport assays without cells were performed in the same way for both 
substances, except the sampling intervals were shortened to 2 min, 
5 min, 7 min, 10 min and 15 min. 
Transport experiments with polystyrene model particles. The parti-
cles used for permeability experiments of the blank filters were also used 
for transport experiments with Calu-3 cells. The cells were incubated 
with 224 µg/ml of particle dispersed in KRB + 1 % BSA for 6 h. The 
quantification was performed as described above and the amount of par-
ticles transported was calculated in relation to the initial amount of par-
ticles used.  
Transport experiments with metal oxide nanoparticles. Prior to use, 
the particles were sterilized by γ-irradiation as described earlier (see 
chapter 2.3) to avoid contamination of the cells during the transport as-
say. Also, the snap-on lid glasses and magnetic stirrers were sterilized as 
described in chapter 2.3 and particle dispersions prepared under sterile 
conditions. Cells were grown on filter inserts with a pore size of 3 µm and 
cultured for 7-10 days. Only cells that reached TEER values of 800 Ωcm2 
or more were used. The preparation of the particle dispersion was follow-
ing the protocol of the project NanoCare we described earlier (see chapter 
2.3). In a concentration of 224 µg/ml (corresponding to 100 µg/cm2), the 
particles were dispersed in RPMI 1650 medium + 10 % FCS Gold. The 
incubation time was 6 or 24 h at 37 C° under gentle shaking (200 rpm). 
Before incubation, 0.1 ml from each compartment was taken and diluted 
in 9.9 ml of the dispersion medium. At the end of the experiment, TEER 
was checked. The apical as well as the basolateral compartment were ex-
tracted and washed 3 times with dispersion medium (apical compart-
ments with 0.5 ml, basolateral compartments with 1.5 ml). The samples 
of each compartment were pooled in a test tube and filled up to a volume 
of 10 ml, leading to a dilution of 1:20 for the apical and 1:6.7 for the ba-
solateral compartments. For determination of the amount of nanoparticle 
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in the cell layer and filter membrane, the Transwells were immersed with 
4 ml of dispersion medium + 1 % Triton X and incubated for 0.5 h at 
37 °C under gentle shaking. Finally, those 4 ml were withdrawn by suc-
tion and pooled with the dispersion medium from two washing steps (2 x 
3 ml of dispersion medium + 1 % Triton X, leading to a total volume of 10 
ml). All samples were frozen at -80 °C until quantification of the metal 
with Inductively coupled Plasma Mass Spectrometry (ICP-MS) or Induc-
tively coupled plasma optical emission spectrometry (ICP-OES).  
Quantification of metal oxide nanoparticles. Only the metal ion 
was quantified and afterwards related by means of atomic mass to the 
nanoparticle oxides. Furthermore, all dilution factors were taken into ac-
count. 
Quantification of ZrO2 and AlOOH with inductively coupled plasma 
optical emission spectrometry (ICP-OES). ZrO2. Standard Zr solutions 
in 3 % HCl in H2O (200 ppm, 100 ppm, 20 ppm, 10 ppm, 2 ppm, 1 ppm) 
were prepared and diluted 1:10 in RPMI medium + 10 % FCS to prepare 
a calibration line. The accuracy of the calibration line was controlled by 
comparison to the Zr-specific signals at 343.823 nm and 339.198 nm. 
Measurements were performed with a Spektro Flame D with a Crossflow 
vaporizer and a flow of 1.6-1.8 ml/min (high frequency generator 1200 
W). At the sample injector equilibrium was established by a higher flow 
rate for 15 s. Samples were measured and compared to the calibration 
line to quantify the Zr concentration of the samples. After 15-20 meas-
urements, the optics were repositioned and the calibration line remeas-
ured before further sample investigation. The resulting Zr concentrations 
were converted to the corresponding ZrO2 amount. The limit of detection 
was 0.5 ppm for the Zr ions. 
AlOOH. 200 ppm of AlOOH was solubilized in concentrated H2SO4 prior 
to dilution in 1 % H2SO4 to a calibration line (concentrations 50 ppm, 20 
ppm, 10 ppm, 2 ppm, 1 ppm). The calibration line was controlled by 
measurement of an Al standard solution (1 mg/ml) at 394.401 nm and 
396.152 nm. Sample measurement was performed analogue to Zr and 
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also converted to the corresponding AlOOH amount. Also here, the limit 
of detection was 0.5 ppm. 
Quantification of CeO2 A and C as well as TiO2 A and B with Induc-
tively Coupled Plasma Mass Spectrometry (ICP-MS). CeO2 A and C. 
After disintegration of the particles with nitric acid, the Cerium content of 
the solution was determined with ICP-MS (Agilent 7500a, with a Mein-
hardt vaporizer and a 1300 W generator). As an internal standard, 45Sc 
was used; the limit of detection was 0.1 ppm for the metal ion. 
TiO2 A and B. Thawed and homogenized samples were disintegrated with 
nitric acid and hydrofluoric acid by means of pressurized vessel digestion 
in a microwave autoclave (UltraClave III, Milestone, Leutkirch, Germany). 
Measurement was performed by ICP-MS (ThermoFisher, X-Series-2, 
Bremen, Germany). The instrument was equipped with a microconcentric 
nebulizer (AHF, Tübingen, Germany) and run at a generator power of 
1300 W. Indium was used as internal standard at a concentration of 
1 µg/l. 49Ti was used as the analyte isotope for the evaluation of the re-
sults. According to the lowest calibration point the limit of quantification 
was estimated at 0.5µg/ml. 
Physico-chemical characterization of the metal oxide nanoparticles. 
For detailed characteristics of the particles, see Table 5.1. The particles 
were varying in their bulk material, although we investigated two TiO2 
particles, with or without organic modification. Also, we used two CeO2 
particles, whereas the CeO2 A particles had a smaller primary particle 
size, a much bigger surface and were slightly less acidic than CeO2 C. For 
details on the methodologies for particle characterization, see chapter 
3.3.  
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Table 5.1. Characteristics of the used metal oxide nanoparticles (data adopted from [35]; n.d.: not determined). 
sample 
chemical composi-
tion, crystallinity 
mean primary particle 
size, morphology 
BET surface 
area 
[m2/g] 
surface chem-
istry 
[At%] 
organic modi-
fication 
pH# 
solubility 
in water 
[ppm] 
ZrO2 
ZrO2 monoclinic 
Baddelyite tetragonal 
14 nm, irregular but 
globular 
122 
O 55 
Zr 21 
C 24 
Cl 0.6 
Organic acid 
with mass = 180 
g/mol 
3.7 190 
AlOOH 
82.7 % AlOOH; 
impurities: C, Na, Fe, 
Si, Li, B 
40 nm, 
irregular but spherical 
 
47 
O 62 
Al 32 
C 7 
 
none 4.3 n.d. 
TiO2 A 
O 58 % 
Ti 41 % 
Cl > 1 % 
anatase 95 %, rutile 5 
% 
17 nm 
irregular but spherical 
117 
O 53 
Ti 21 
C 25 
Cl 1 
yes 5.4 10 
TiO2 B 
>99.5 % TiO2 
rutile and anatase, 
tetragonal 
27 nm irregular but 
globular 
52 
O 58 
Ti 26 
C 14 
N 0.5 
Cl 1 
none 6.1 130 
CeO2 A > 99.97 % purity 
14 nm 
cubic, aggregated 
63 
O 57 
Ce 25 
C 18 
none 5.9 n.d. 
CeO2 C 
>99 % CeO2 
Cerianite, cubic 
70 nm irregular but 
globular 
33 
O 53 
Ce 26 
C 20 
Cl 0.6 
none 5.9 > 1 
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5.4 Results & Discussion 
Adaptations of the Calu-3 air-blood barrier model to nanoparticles. 
Normally, filters with a pore size of 0.4 µm are used within the Transwell 
system, but as shown in Figure 5.2, this filter material even used without 
a cell layer provided a significant barrier to particles up to 200 nm. 
Hence, filters with a pore size of 3 µm were tested. Clearly, this change 
revealed a transport of up to 100 % of the theoretical equilibrium concen-
tration in the acceptor after an incubation period of 6 hours only, which 
is a prerequisite for further studies with cell layers. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Permeation of model particles through blank filters with different 
pore sizes: After 6 h of incubation, up to total concentration equilibrium was 
achieved for particles permeated through the filter with the large pores, 
whereas a pore size of 0.4 µm was a significant barrier for particle permea-
tion (c=carboxylated; p=plain; the number corresponds to the particle di-
ameter; shaking rate 200 rpm; mean + sd). 
 
 
These results indicated that the use of filter inserts with a pore size of 
3 µm is needed to perform particle-related transport assays without tak-
ing the likelihood of wrong negative results. 
p50 p100 c50 c100 c200
0
20
40
60
80
100
120
th
e
o
re
ti
c
a
l 
e
q
u
ili
b
ri
u
m
 c
o
n
c
. 
[%
]
particle
 0.4 µm pore size
 3 µm pore size
 86 
Since the larger pore size is very big relative to the cells used, the rele-
vant cell characteristics had to be investigated. As mentioned in Figure 
5.1, the cells could grow into the pores or even on both sides of the fil-
ters, leading to reinforcement of the barrier and hence falsification of 
permeation rates. Comparison of cross sections of Calu-3 cells on filter 
inserts with 0.4 µm or 3 µm pore size respectively did not reveal any visi-
ble difference in morphology (Figure 5.3). Also, the cells did grow only on 
the surface of the filters, no invasion into the pores or even growth on 
both sides of the filters occurred. 
 
 
 
Figure 5.3. Calu-3 cell monolayers on filter inserts with different pore sizes: 
a) pore size of 0.4 µm, Calu-3 cells at day 7; b) pore size of 3 µm, Calu-3 
cells at day 10. Clearly, the different size of the pores can be recognized. 
Both pictures show a confluent cell monolayer without intercellular spaces. 
Hence, no differences in morphology can be seen for both monolayers.  
(seeding density 105 cells/cm2; TEER values > 800 Ωcm2; magnification 
100x) 
 
 
Still, similar morphologies alone are no sufficient indicator for analogous 
barrier properties. Hence, we investigated the integrity of the monolayer 
by measuring the TEER profile. As can be seen in Figure 5.4, Calu-3 cells 
grown on filter inserts with both pore sizes reached TEER values of more 
than 1000 Ωcm2, but the maximum for cells grown on the filters with 
3 µm pores was lower than for the smaller pore size. Also, the time frame 
in which the cells kept up these high TEER values was for the larger pore 
size much shorter (4 days) than for the cells on the smaller pores (up to 9 
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days). For Calu-3 cells on filters with 0.4 µm pores, a seeding density of 
7.5·104 cells per well (equals an area of 1.12 cm2) was sufficient, whereas 
the optimal seeding density for growth on larger pores should be in-
creased to 105 cells/well, as less cells lead to a slower increase of TEER 
values and a shortened time period for experiments (Figure 5.4). In litera-
ture, TEER values from 400 to 600 Ωcm2, but also from 700 up to 
2500 Ωcm2 were reported [139-141]. Geys and colleagues postulated the 
Calu-3 monolayers to be tight at a TEER of 575 Ωcm2 for the 0.4 µm 
pores and  at 420 Ωcm2 for filters with 3 µm pore size [142]. Although dif-
ferences in the TEER profile could be detected, an intact barrier function 
seemed to be given also with filters of the larger pore size.  
 
 
Figure 5.4. TEER profiles of  Calu-3 cells grown on filter inserts with differ-
ent pore sizes: Both pore sizes lead to TEER values of more than 1000 Ωcm2, 
although the time line are varying. For Calu-3 cells on filters with a pore size 
of 3 µm the maximum is lower and is reached earlier than on filters with the 
smaller pore size. Also, the time frame for experiments is with 4 days for the 
larger pores size shorter than 9-10 days, respectively (mean ± sd, n=9). 
 
 
Although the integrity of the monolayer could be proven, the bigger pore 
size still might have an influence on transport patterns. We calculated 
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the total “pore area” of both filters to be 5·10-3 cm2 (0.4 µm pore size) or 
0.14 cm2 (3 µm pore size), respectively. This results in the much higher 
relation of this “pore area” compared with total filter area, although both 
filters have equal dimensions (see Figure 5.1). A larger pore area means 
also more contact of the cells with the basolateral compartment, hence, 
an altered transport pattern of the cells due to this fact had to be 
checked. Transport assays with well characterized soluble model sub-
stances were performed with filter inserts of both pore sizes with and 
without cell monolayers and compared. As high permeability marker the 
lipophilic drug propranolol was used, the hydrophilic sodium-fluorescein 
was the model substance for low permeation. Clearly, the cell monolayer 
with its lipophilic membrane is only a weak barrier to propranolol, and 
no significant difference in permeation could be detected for both pore 
sizes. Also, there was no difference between the two filters without the 
cells, suggesting permeation not only through the pores, but through the 
whole filter area. It might be speculated that diffusion not only occurs 
through the pores, but also through the PET membrane, diminishing the 
effect of the larger pore area/filter area ratio of the filters with the 3 µm 
pore size. For the filters with the smaller pores, the Papp value for the low 
permeation marker sodium fluorescein was in very good agreement with 
literature [143]. However, the Papp value for sodium-fluorescein was about 
five times higher for the larger pore size, but experiments without cells 
clearly confirm this to be due to the larger diffusion area in favour of the 
filters with 3 µm pores, as the same ratio occurred in experiments with-
out cells (see Table 5.2). In contrast to propranolol, the filter material 
seems to be an effective barrier and permeation occurs through the pores 
only. These results confirm that no change in transport patterns oc-
curred; the higher Papp-value for the low permeability marker was caused 
by simple physics.  
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Table 5.2. Papp values for propranolol as high and sodium-fluorescein as low 
permeability marker, tested with and without cell monolayers, to confirm 
similar transport patterns for Calu-3 cells on both filter inserts (TEER for 
experiments containing Calu-3 cells > 800 Ωcm2 before and after transport 
assays; mean ± sd, n=3). 
 
Papp high permeability marker 
(Propranolol-HCl) 
[cm/s] 
Papp low permeability marker 
(Sodium-Fluorescein) 
[cm/s] 
pore size filter only cell monolayer filter only cell monolayer 
0.4 µm 7.34 ± 1.19·10-5 3.13 ± 0.22·10-5 3.83 ± 0.09·10-5 1.61 ± 0.05·10-7 
3 µm 7.2 ± 0.25·10-5 4.86 ± 0.35·10-5 20.6 ± 0.5·10-5 9.37 ± 0.38·10-7 
ratio 3 
µm/0.4 µm 
1 1.5 5.4 5.82 
 
 
Transport experiments with polystyrene model particles. As proof of 
the functionality of the adapted barrier model, transport experiments 
with polystyrene model particles with a size range from 50 to 200 nm 
were performed. Clearly, a particle transport of up to 4 % after 24 h of 
incubation could be seen (Figure 5.5), which is corresponding well to the 
transport rates found in literature for Calu-3 cells [142]. Smaller particles 
seem to be transported in higher amounts than the larger 200 nm parti-
cles, but only the plain 50 nm particle showed a significantly higher 
transport rate compared to the larger particles. A generally increased 
transport for the plain particles cannot be confirmed. To rule out 
transport of the fluorescent dye only after cleavage from the particle, the 
presence of particles in basolateral samples was tested via Dynamic Light 
Scattering. In all samples, particles could be detected of the same size as 
applied in the apical compartment. 
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Figure 5.5. Transport of model polystyrene particles over Calu-3-cell mono-
layers grown on supports with 3 µm pore size from apical to basolateral side 
after an incubation time of 24 h. The TEER for the Calu-3 cells exceeded 800 
Ωcm2 before and after transport assays. Significant differences are marked 
with a (*) (p=plain particle without surface modifications, c=carboxylated 
surface; numbers represent the diameter of the particle; mean + sd; n=3; 
statistics: One way ANOVA, followed by pair wise multiple comparison with 
Holm-Sidak-method, p<0.05). 
 
 
Transport of metal oxide nanoparticles. The transport assays with 
metal oxide nanoparticles were performed with a particle concentration of 
100 µg/cm2 (=224 µg/ml) for 6 and 24 h of incubation under sterile con-
ditions. The transport results are summarized in Table 5.3: All of the par-
ticles tested permeated through the naked filter, i.e. the filter pores were 
no significant obstacle for particle permeation. For ZrO2, AlOOH and both 
TiO2 particles neither a transport nor particle uptake into the cell or ad-
hesion onto the cell surface could be detected. This is in good agreement 
with in vivo short and long-term inhalation studies performed with the 
very same TiO2 and AlOOH particles, as no translocation into liver, kid-
ney, spleen or basal brain with olfactory bulb could be detected [35, 144]. 
In those inhalation studies, also CeO2 C was tested negative for translo-
cation into the mentioned organs. This is in contrast to our findings, as 
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we could prove a particle transport similar to that of the carboxylated 
100 nm model particle (see Figure 5.5). Also, cerium could be detected in 
the cell lysates and filter washout samples, indicating a transcellular 
transport of the CeO2 particles. The particle concentrations for CeO2 C in 
the in vivo assay was with a maximum concentration of 10 mg/m3 
(= 0.01 µg/ml) much lower than the concentration tested here 
(100 µg/cm2= 224 µg/ml). Therefore, an overload effect may be a plausi-
ble explanation for the transport detected. Still, a decrease in concentra-
tion was not possible due to the detection limits of ICP-MS.  
 
 
Table 5.3. Summary of transport assays performed with metal oxide nano-
particles after an incubation time of 24 h; Except for both CeO2 particles, no 
transport could be detected (n=3; mean ± sd). 
nano-
particle 
theoretical equilibrium 
conc. through naked 
filter  [%] 
transport through 
cells after 24 h [%] 
cellular uptake & 
filter washout after 
24 h [%] 
ZrO2 54.6 ± 5.8 0 0 
AlOOH 62.2 ± 25.5 0 0 
TiO2 A 27 ± 4.9 0 0 
TiO2 B 46.4 ± 5.4 0 0 
CeO2 A 31.9 ± 5.6 3.5 ± 1.3 3.5 ± 1.3 
CeO2 C 75.9 ± 50.2 3.2 ± 0.1 5.5 ± 2.1 
 
 
The TEER value is an indicator of an intact epithelial cell monolayer with 
proper barrier functions. Hence, when the monolayer is compromised, 
the TEER is decreasing. Controlling of the TEER before and after the in-
cubation with ZrO2 particles revealed a significant decrease of TEER after 
24 h compared to the negative control (Table 5.4). Although the barrier 
seemed to be compromised, no ZrO2 translocation could be detected. In 
all experiments, also the negative controls, TEER (treated with dispersion 
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medium instead of particle dispersion) decreased after 24 h. The same 
ZrO2 particles (concentrations of 0.1 -10 µg/cm2) tested on MDCK II and 
NRK52E cells had no effect on TEER [35]. Hence, the TEER decrease for 
ZrO2 is more likely to be due to the experimental procedure or also an 
overload effect.  
 
 
Table 5.4. TEER values of the cells after 6 or 24 h of incubation with 
(=samples) or without nanoparticles (=negative contr.). The data are rela-
tive to the TEER measurements taken immediately before incubation (mean 
± sd). The only particle revealing a significant decrease in barrier function is 
ZrO2 after an incubation of 24 h (grey cells; P=0.95). 
 TEER after 6 h incubation [%] TEER after 24 h incubation [%] 
 sample 
negative 
contr. 
sample negative contr. 
ZrO2 79.7 ± 9.7 86.6 ±  2 47.4 ± 6.8 69.8 ± 3.5 
AlOOH 58.5  ± 10.6 47.7 ± 3.4 29.6 ± 1.3 49.8 ± 16.3 
TiO2 A 82.9 ± 5.1 68.1 ± 6.4 29.6 ± 3.7 23.8 ± 3.7 
TiO2 B 85.1 ± 2.3 83.6 ± 5 21.1 ± 0.2 21.4 ± 1.3 
CeO2 A 104.3 ± 26.2 74 ± 17.8 39 ± 8.9 34.4 ± 9.6 
CeO2 C 54.9 ± 17.3 46.3 ± 6.8 43.3 ± 5.9 37.4 ± 6.2 
 
 
5.5 Conclusion 
To test the transport of nanoparticles with the air-blood barrier model 
Calu-3, the model had to be adapted by adjusting the pore size of the fil-
ter inserts the cells are grown on. Clearly, this change did not influence 
the transport patterns of the cells, although the seeding density as well 
as the time frame for experiments had to be adjusted. The functionality of 
the model was proven with polystyrene model particles prior to experi-
ments with much more complicated to handle metal oxide nanoparticles. 
Although the TEER values decreased in all experiments, no translocation 
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was detected for ZrO2, TiO2 A and B and for AlOOH. Only CeO2 A and C 
revealed a transport. As metal oxide nanoparticles are not easily detected 
and quantified, determination of transport rates is a challenging task, 
whereas the optimal experimental setup is still to be improved. 
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Summary and outlook 
 
Industrial nanoparticles are not developed to be compatible with in vitro 
cell culture assays which are carried out in isotonic solutions at physio-
logical pH and often in the presence of proteins. The tendency of nano-
particles to deagglomerate or agglomerate is strongly sensitive to these 
parameters. The state of agglomeration and the protein corona bear an 
important influence on the level of toxic effects via the change of 
transport mechanisms and surface coating. Here the interaction of nano-
particles with physiological media for in-vitro nanotoxicology experiments 
was rigorously characterized. Beyond adsorption of proteins on metal ox-
ide and polymeric nanoparticles, nanoparticle deagglomeration due to 
adsorbing proteins acting as protection colloids was quantified. Previous-
ly neglected, but indispensable testing of sterility and measures to ensure 
it were reported. These findings resulted in a checklist of pre-
requirements for dispersion of nanoparticles in physiological media and 
for reliable attribution of potential toxic effects. 
Once nanoparticles have entered the body, they can interact with the 
physiological surroundings, i.e. also with proteins. This particle-protein 
interaction might lead to altered reactions concerning the particles, influ-
encing their bio-persistence in the body. Hence, the investigation of pro-
tein adsorption onto those particles is of great importance. Here, the pro-
tein adsorption of Bovine Serum Albumin to three CeO2 nanoparticles 
with only slightly different physico-chemical properties were investigated 
and compared with Atomic Force Spectroscopy, Analytical Ultracentrifu-
gation and BCA-assay. All adsorption processes could be fitted with a 
sigmoid mathematic model, revealing differences in half-maximal adsorp-
tion for especially one of the three particles. Clearly, particles of the same 
bulk material do not necessarily reveal the same adsorption pattern for 
proteins, and the state of agglomeration must be taken into account to 
interpret the results correctly. Also, it was shown that the protein might 
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alter its shape during adsorption process specifically for the different par-
ticles tested. It can be concluded that even small differences concerning 
particle properties can lead to different protein adsorption and hence 
might provoke different reactions in the body. This means that testing of 
one particle of a bulk material as reference is not enough to determine 
the potential toxicity of nanomaterials. 
After inhalation, the Alveolar Lining Fluid (ALF) covering the respira-
tory epithelium of the deep lung is the first biological barrier encountered 
by nanoparticles. Hence, the adsorption of Surfactant protein A, the pre-
dominant protein component of pulmonary surfactant (an integral part of 
ALF), was investigated. For the first time significant differences for metal 
oxide nanoparticles to the binding of Sp-A were reported. Sp-A is a phys-
iologically most relevant protein and provides important biological sig-
nals. Also, it is involved in the lung's immune defense, controlling e.g. 
particle binding, uptake or transcytosis by epithelial cells and macro-
phages. In this work, different particle-protein interactions for eight dif-
ferent nanoparticles were proven, whereas particles of the same bulk ma-
terial revealed different adsorption patterns. In contrast to other proteins 
as Bovine Serum Albumin (BSA), Sp-A does not seem to significantly de-
agglomerate large agglomerates of particles, indicating different adsorp-
tion mechanisms as in the well-investigated model protein BSA. These 
findings may have important consequences for biological fate and toxico-
logical effects of inhaled nanomaterials. 
Inhaled nanoparticles could not only adsorb physiologically relevant Sur-
factant components, but also translocate over the air-blood barrier. The 
for soluble substances well established Calu-3 in vitro air-blood barrier 
model was adapted to the use of nanoparticle transport testing. As the 
usually used filter supports hindered particle transport due to their small 
pore size, supports with a pore size of 3 µm had to be used. On those fil-
ters, barrier and transport characteristics of the cells were tested and 
culture conditions changed to gain optimal conditions. Functionality was 
confirmed with transport experiments with polystyrene model particles 
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prior to testing of industrially relevant engineered metal oxide particles. 
Except for two different CeO2 nanoparticles, no transport across the epi-
thelial barrier model could be detected. For ZrO2 nanoparticles, a com-
promised barrier function could be seen. 
In chapter 5, we mentioned the possible transport routes for nanoparti-
cles over our epithelial model. As we have proven for polystyrene model 
particles, some nanomaterials can be transported via those routes. How-
ever, an expansion of the epithelial model to a triple cell culture, contain-
ing macrophages on the apical and Dendritic cells on the basal side [145-
147], reveals more possibilities of overcoming the epithelial barrier. Blank 
and colleagues. could show that polystyrene particles with a size of 1 µm 
were rarely taken up by the epithelial cells, but by the macrophages and 
the Dendritic cells, either by extensions or total migration of the Dendrit-
ic cells through the epithelium. Also, particle transport between Dendritic 
cells and between Macrophages and Dendritic cells could be shown [148]. 
This particle transport is not disrupting the integrity of the epithelial lay-
er [149]. Those transport routes might be relevant for the tested particles, 
too, i.e. a negative result with our “epithelium only” model does not guar-
antee no transport is happening at all. In the future, further investiga-
tions with those triple cell cultures, mimicking reality more closely, might 
bring new insights in the transport pattern of metal oxide particles. Fur-
thermore, after thorough comparison, it might be possible to use this ex-
tended triple cell culture model to eventually replace animal testing un-
der certain circumstances. 
Also, the impact of protein adsorption, especially of physiologically rele-
vant proteins like Sp-A, must be investigated more intensely. After re-
finement of the pBALF generation protocol, protein conditioned nanopar-
ticles of the same material, but with different physical properties, i.e. ζ-
potential or hydrophobicity, have to be investigated to correlate Sp-X ad-
sorption to specific particle properties. Although we demonstrated articu-
late differences in protein adsorption on nanoparticles with similar prop-
erties, at least a rough estimate on protein adsorption mechanisms might 
be possible.  
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Conditioning with Sp-X might have some influence on the reaction of the 
cells at the air-blood barrier. Hence, an influence on the particle 
transport and other cell reactions after conditioning should be investigat-
ed. For this purpose, aerosolized conditioned particles could be deposited 
on the before mentioned triple cell culture to compare particle transport 
with or without Sp-A coating.  
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Zusammenfassung und Ausblick 
 
Aufgrund des Herstellungsprozesses industriell gefertigter Nanopartikel, 
wie sie hier verwendet wurden, sind die Partikel nicht kompatibel mit in 
vitro  Testsystemen. Diese Arten von Versuchen müssen, um zellverträg-
lich zu sein, mit Medien im physiologischen pH-Bereich, isotoner Salzlast 
und oft auch unter Anwesenheit von Proteinen durchgeführt werden. 
Diese Parameter sind für die Stabilität der Partikeldispersionen von es-
sentieller Bedeutung, und schon kleine Änderungen können zu Agglome-
ration, aber auch zu Deagglomeration führen. Die tatsächliche Partikel-
größe sowie die Belegung der Partikel mit Proteinen (Ausbildung einer 
sog. Proteincorona) sind für die Abschätzung der Toxizität der Partikel 
von bedeutender Wichtigkeit, da sie einerseits die Aufnahme in den Kör-
per, andererseits die Oberflächeneigenschaften der Partikel verändern. 
Daher wurden die Wechselwirkungen zwischen Metalloxid-Nanopartikeln 
und physiologischen Medien, wie sie in in vitro nanotoxikologischen Tests 
verwendet werden, intensiv charakterisiert. Neben der Adsorption von 
Proteinen an Modell- und Metalloxid-Partikel wurde die Deagglomeration 
der Nanopartikel durch Proteine als Schutzkolloide quantifiziert. Für in 
vitro Langzeitversuche sind außerdem die Sterilität sowie der Endotoxin-
gehalt der Partikel von immenser Bedeutung. Daher wurde eine Möglich-
keit der Sterilisierung der Partikel als auch Parameter aufgedeckt, die bei 
der Bestimmung des Endotoxingehalts beachtet werden müssen. Die Er-
gebnisse gipfeln in einer Checkliste, die die Voraussetzungen zur Disper-
sion der Partikel in physiologischen Medien aufzeigt, um belastbare Da-
ten zur Nanotoxizität von Nanomaterialien zu gewinnen.  
Sobald Nanopartikel in den Körper eindringen, können sie mit der Umge-
bung, d.h. auch mit Proteinen, interagieren. Diese Interaktion kann zu 
veränderten Reaktionen der Körperbarrieren auf die Partikel führen und 
damit die Verweildauer im Körper beeinflussen. Mit Analytischer Ultra-
zentrifugation, Rasterkraft-Spektroskopie und BCA-Protein-
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Quantifizierung wurden die Adsorption von Bovinem Serumalbumin 
(BSA) an drei CeO2-Partikel mit ähnlichen physikalisch-chemischen Ei-
genschaften sowie der Agglomerationsgrad der Partikel untersucht. Die 
Proteinadsorption konnte mit einem sigmoidalen mathematischen Modell 
beschrieben werden und zeigte vor allem bei einem der drei Partikel ein-
deutige Unterschiede in der halbmaximalen Adsorption. Es zeigte sich 
eindeutig, dass Partikel aus gleichem Material und mit sehr ähnlichen 
physikalisch-chemischen Eigenschaften nicht unbedingt auch die glei-
chen Proteinadsorptionsmuster zeigen und dass der Agglomerationsgrad 
in die Beurteilung mit einfließen muss, um die Ergebnisse korrekt zu in-
terpretieren. Des Weiteren fanden sich eindeutige Hinweise darauf, dass 
BSA in unterschiedlicher Konformation an die getesteten Partikel adsor-
biert. Dies bedeutet, dass auch kleine Unterschiede in den Eigenschaften 
der Partikel zu unterschiedlicher Proteinadsorption führen und damit 
verschiedene Reaktionen im Körper hervorrufen kann. Deshalb ist es 
nicht ausreichend, nur einen Partikel eines Materials als Referenz zu tes-
ten und davon auszugehen, dass Partikel mit ähnlichen Eigenschaften 
das gleiche Adsorptionsverhalten und damit auch ein ähnliches nanoto-
xikologisches Potential aufweisen.  
Nach Inhalation ist die erste Barriere, auf die ein Nanopartikel trifft, das 
Alveolar Lining Fluid (ALF), welches die Lungenbläschen zur Luftseite hin 
auskleidet. Deshalb war der nächste konsequente Schritt die Untersu-
chung der Proteinadsorption mit physiologisch relevantem Surfactant-
Protein A (Sp-A), der vorherrschenden Proteinkomponente des pulmona-
len Surfactant (integraler Bestandteil des ALF). Zum ersten Mal über-
haupt konnten Unterschiede in der Proteinadsorption verschiedener in-
dustriell gefertigter Metalloxid-Nanopartikel gefunden werden. Sp-A ist 
ein physiologisch hochrelevantes Protein, das einerseits Signalkaskaden 
innerhalb der Epithelzelle auslöst, andererseits auch immunologische 
Funktion hat: Es opsonisiert Bakterien und andere Pathogene, damit sie 
von Macrophagen erkannt und phagozytiert werden können. Demnach 
könnte eine Adsorption von Sp-A an Nanopartikel eine gesteigerte Auf-
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nahme in Macrophagen als auch ins Alveolarepithel bedeuten. Eine sol-
che Partikel-Protein-Interaktion konnte für acht Nanopartikel bewiesen 
werden, wobei Partikel aus gleichem Material auch hier unterschiedliche 
Adsorption zeigten. Im Gegensatz zu BSA scheint Sp-A keine signifikante 
Deagglomeration der Partikel hervorzurufen, was auf unterschiedliche 
Adsorptionsmechanismen hinweist. Diese Ergebnisse könnten wichtige 
Konsequenzen bezüglich des Verbleibs im Körper als auch des direkten 
toxikologischen Effekts inhalierter Nanomaterialien haben.  
Inhalierte Nanopartikel könnten jedoch nicht nur physiologisch relevan-
tes Sp-A adsorbieren, sondern auch die Blut-Luft-Schranke überwinden, 
sodass sie in den Blutkreislauf und somit in den Körper gelangen. Um 
den Partikeltransport über diese Körperbarriere in vitro zu testen, wurde 
das für lösliche Substanzen seit längerem etablierte Calu-3 Modell auf 
Transwell-Filtern an die Besonderheiten von Nanopartikeln angepasst. 
Da die üblicherweise benutzten Filter mit einer Porengröße von 0,4 µm 
eine deutliche Barriere für die Partikel darstellten, musste auf eine Po-
rengröße von 3 µm gewechselt werden. Um optimale Versuchskonditio-
nen zu erreichen, mussten die Kulturbedingungen an die größeren Poren 
angepasst werden. Außerdem wurden die Barriere- sowie Transportei-
genschaften auf diesen Filtern bestätigt. Die Funktionalität des veränder-
ten Modells wurde vor Durchführung von Transportversuchen mit Me-
talloxid-Partikeln mittels Polystyren-Modellpartikeln verifiziert. Mit 
Ausnahme von beiden getesteten CeO2-Partikeln konnte für keinen der 
Metalloxid-Partikel weder eine Aufnahme in die Zelle noch ein Transport 
über die epitheliale Barriere bestimmt werden. ZrO2-Partikel schienen 
eine Beeinträchtigung der Barriereeigenschaften zu verursachen, was je-
doch wahrscheinlich ein Overload-Effekt gewesen ist.  
Mögliche Transportwege für Nanopartikel über epitheliale Barrieren wur-
den in Kapitel 5 bereits erwähnt. Wie hier mit den Polystyren-
Modellpartikeln gezeigt werden konnte, kann Partikeltransport über ei-
nen dieser Wege funktionieren. Mit einer Ausweitung des Barrieremodells 
mit zusätzlichen Macrophagen auf der apikalen und Dendritischen Zellen 
auf der basalen Seite [145-147] konnten bereits weitere Möglichkeiten, 
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die epitheliale Barriere zu überwinden, aufgezeigt werden: Blank und 
Mitarbeiter haben gezeigt, dass Partikel mit einem Durchmesser von 
1 µm zwar kaum von den Epithelzellen eines solchen Modells, jedoch von 
den Macrophagen und Dendritischen Zellen aufgenommen werden, ent-
weder durch Ausbildung von Ausläufern oder durch komplette Wande-
rung der Dendritischen Zellen durch das Epithel auf die apikale Seite. 
Außerdem konnte ein Partikelaustausch zwischen den Macrophagen und 
Dendritischen Zellen beobachtet werden [148], der die Barriereeigen-
schaften der Epithelzellen nicht beeinflusste [149]. Auch diese Transport-
routen könnten für den in der Realität stattfindenden Partikeltransport 
relevant sein, daher ist ein negatives Ergebnis aus Transportversuchen 
mit Modellen, die ausschließlich aus Epithelzellen besteht, nicht ausrei-
chend. Eine Übernahme eines solchen Tripelzellkultur-Modells könnte 
neue Einsichten auch in den Transport von Metalloxid-Nanopartikeln 
bringen, da diese die Realität besser widerspiegeln. Nach ausführlichem 
Vergleich mit in vivo Versuchen könnte es somit sogar möglich sein, dies 
unter gewissen Umständen als Ersatzmodell für Tierversuche zu nutzen. 
Der Einfluss der Proteinadsorption, besonders der von physiologisch re-
levanten Proteinen wie Sp-A, muss weiter intensiv untersucht werden, 
um das toxikologische Potential von Nanopartikeln besser abschätzen zu 
können. Nachdem das Protokoll zur BALF-Gewinnung weiter verfeinert 
wurde, könnten Adsorptionsversuche mit Partikeln aus gleichem Materi-
al, jedoch mit unterschiedlichen physikalischen Eigenschaften, z.B. ζ-
Potential oder Hydrophobizität, helfen, diese Eigenschaften einer be-
stimmten Sp-A-Adsorption zuzuordnen. Obwohl in Kapitel 3 gezeigt wur-
de, dass auch Partikel mit ähnlichen physikalisch-chemischen Eigen-
schaften unterschiedliche Proteinadsorption zeigen können, wäre 
eventuell wenigstens eine grobe Abschätzung der Proteinadsorptionsme-
chanismen möglich.  
Konditionierung mit Surfactant-Proteinen kann, wie bereits erwähnt, ei-
nen Einfluss auf die zelluläre Reaktion an der Blut-Luft-Schranke haben. 
Deshalb sollte der Einfluss der Poreincorona auf Partikelaufnahme und –
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Transport untersucht werden. Zu diesem Zweck könnten aerosolisierte, 
mit Proteinen konditionierte Nanopartikel auf das o.g. Tripelzellkultur-
Modell deponiert und mit dem Transportverhalten unkonditionierter Par-
tikel verglichen werden.  
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Abbreviations 
 
ALF     Alveolar lining fluid 
AlOOH    Aluminumoxide-Hydroxide 
APS     Ammoniumpolysulfate 
AUC     Analytical Ultracentrifugation 
BaSO4    Bariumsulfate 
BCA-assay   Bicinchinoninic Acid assay 
BET surface   Brunauer, Emmett, Teller surface 
BMBF    Bundesministerium für Bildung und Forschung 
BSA     Bovine serum albumin 
c50, c100, c 200 carboxylated Polystyrene nanoparticles with a 
diameter of 50, 100 or 200 nm 
CNTs    Carbonanotubes 
DLS     Dynamic Light scattering 
DMEM    Dulbecco´s Modified Eagle Medium 
FCS     Fetal Calf Serum 
FITC-BSA   BSA, labelled with Fluorescein-Isothiocyanate 
HSA     Human serum albumin 
ICP-MS    Inductively Coupled Plasma Mass Spectrometry 
ICP-OES inductively coupled plasma optical emission 
spectrometry 
KRB     Krebs-Ringer buffer 
LAL     Limulus amebocyte lysate 
CeO2    Ceriumdioxide  
NP(s)    nanoparticle(s) 
NTB/BCIP Nitro blue tetrazolium chloride/ 5-Bromo-4-
chloro-3-indolyl phosphate,toluidine salt 
OM     surface modifier 
p50, p100 plain Polystyrene nanoparticles with a diameter 
of 50 or 100 nm 
PB     Phosphate buffer 
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pBALF    porcine Broncheoalveolar Lavage Fluid 
PNIPAM     Poly(N-isopropylacrylamide) 
REACH Registration, Evaluation, Authorization and Re-
striction of Chemicals 
rpm     rounds per minute 
SDS-(PAGE) Sodiumdodecylsulfate-Polyacrylamid-
Gelelectrophoresis 
Sp-A, B, C, & D  Surfactant protein A, B, C, & D 
Sp-X    collective term for Surfactant proteins A to D 
TBS     Tris-buffered saline 
TEM    transmission electron microscopy 
TEER    Transepithelial Electrical Resistance 
TiO2     Titaniumdioxide 
TOF-SIMS   time of flight secondary ion mass spectrometry 
TRIS-HCl Tris(hydroxymethyl)-aminomethan-hydrochloric 
acid 
TWEEN 80 Polysorbate 80 
XPS     X-ray photoelectron spectroscopy 
XRD     X-ray diffraction 
ZrO2    Zriconiumdioxide
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